BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>editorial.bmjopen@bmj.com</u>

# **BMJ Open**

## Reduction in sympathetic tone in Obstructive sleep apnea patients: is fixed CPAP more effective than APAP? – a randomized, parallel trial protocol

Journal:	BMJ Open
Manuscript ID	bmjopen-2018-024253
Article Type:	Protocol
Date Submitted by the Author:	18-May-2018
Complete List of Authors:	Treptow, Erika; 1. Université Grenoble Alpes, Pepin, Jean; Hôpital Universitaire de Grenoble, Bailly , Sebastien; Centre Hospitalier Universitaire Grenoble Alpes Hopital Michallon Levy, P; Hypoxia Pathophysiology (HP2) Laboratory Joseph Fourier University Bosc , Cecile ; Centre Santé et Sommeil Destors, Marie; Centre Hospitalier Universitaire Grenoble Alpes Hopital Michallon Woehrle, Holger; Lung Center Ulm Tamisier, Renaud; Univ. Grenoble Alpes, HP2; Inserm, U1042; Grenoble Alps University Hospital, EFCR Laboratory
Keywords:	obstructive sleep apnea, Hypertension < CARDIOLOGY, continous positive airway pressure, SLEEP MEDICINE, sympathetic activity

SCHOLARONE<sup>™</sup> Manuscripts

1 2		
2 3 4	1	Reduction in sympathetic tone in Obstructive sleep appea patients:
5	T	Reddetion in sympathetic tone in obstructive sleep aprica patients.
6 7	2	is fixed CPAP more effective than APAP? – a randomized, parallel
8 9	3	trial protocol
10 11	4	Erika Treptow <sup>1</sup> , Jean-Louis Pépin <sup>1</sup> , Sebastien Bailly <sup>1</sup> , Patrick Levy <sup>1</sup> , Cecile Bosc <sup>2</sup> , Marie
12 13	5	Destors <sup>1</sup> , Holger Woehrle <sup>3</sup> , Renaud Tamisier <sup>1</sup>
14 15	6	
16 17	7	1. University Grenoble Alpes, HP2 laboratory; Inserm U1042, Grenoble, France and
18 10	8	Grenoble Alpes University Hospital, EFCR Laboratory, Thorax and Vessels Division,
20 21	9	Grenoble, France.
21	10	2. Health and Sleep Center, Grenoble, France.
23 24 25	11	3. Sleep and Ventilation Center Blaubeuren / Ulm Lung Center, Ulm, Germany
26 27	12	Sponsor: Grenoble Alpes University Hospital
27 28 29	13	CS 10217, 38043 Grenoble Cedex 09 France
30 31	14	Corresponding authors: Renaud Tamisier and Erika Treptow
32	15	EFCR Laboratory, Grenoble Alpes University Hospital
33 34 35	16	CS 10217 Grenoble 38043 Cedex 09 France
36 37	17	e-mail: <a href="mailto:rtamisier@chu-grenoble.fr">rtamisier@chu-grenoble.fr</a>
38 39 40	18	Phone: +33 (0)4 76765516
41 42	19	Sources of support: ET is supported by the Coordenação de Aperfeiçoamento de Pessoal de
43	20	Nível Superior (CAPES) – Brazil. This work was supported by unrestricted grants from
45	21	ResMed, foundation Agir pour les maladies chroniques and by the French National Research
46 47 48	22	Agency in the framework of the "Investissements d'avenir" program (ANR-15-IDEX-02).
49 50	23	Word count: 2994
51 52	24	Number of figures and tables: 2 figure and 2 tables
53 54 55	25	
56 57	26	
58		1
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1		
2	1	
3 4	T	
5 6	2	Abbreviations:
7 8	3	ABPM: ambulatory BP monitoring
9 10	4	AHI: apnea and hypopnea index
11 12	5	APAP: auto-adjusting continuous pressure
13 14	6	BP: blood pressure
15 16	7	CPAP: continuous positive airway pressure
17 18	8	DBP: diastolic blood pressure
19 20	9	ECG: electrocardiography
21 22	10	EEG: electroencephalography
23 24	11	EMG: electromyography
25 26	12	EOG: electrooculography
27 28	13	HRV: heart rate variability
20 29 30	14	ITT: intention-to-treat analysis
31 32	15	MBP: mean blood pressure
33 34	16	MSNA: muscle sympathetic nerve activity
35 26	17	OSA: obstructive sleep apnea
30 37	18	PPT: per protocol analysis
38 39	19	SBP: systolic blood pressure
40 41	20	
42 43	21	
44 45	22	
46 47	23	
48 49	24	
50 51	25	
52 53	26	
54 55	27	
56 57	28	
58		
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 3 of 32

#### BMJ Open

## 1 Abstract (Word count: 288)

Introduction: Obstructive sleep apnea (OSA) is a prevalent chronic disease associated with fatal and non-fatal cardiovascular events. Hypertension is one of the major intermediary mechanisms leading to late cardiovascular events. Intermittent hypoxia and hypercapnia associated with nocturnal acute respiratory events stimulate chemo- reflexes which in turn result in sympathetic over-activity and finally blood pressure elevation. Continuous positive airway pressure (CPAP) is the primary treatment for OSA and induces a small but significant reduction in blood pressure. The use of auto-adjusting continuous pressure (APAP) modalities has increased in the last few years and several studies have suggested different ranges of blood pressure (BP) reduction when comparing fixed CPAP versus APAP. However, the pathophysiological mechanisms implicated are not fully elucidated. The variations in pressure through the night inherent to APAP use may induce persistent respiratory efforts and sleep fragmentation that might impair sympathovagal balance during sleep and result in smaller decreases in BP. Therefore, this study aims to compare muscle sympathetic nerve activity (MSNA) assessed by microneurography (the reference method for measuring sympathetic activity) after one month of APAP versus fixed CPAP in treatment-naive OSA patients.

Methods and analysis: adult subjects with newly diagnosed OSA (apnea hypopnea index > 20/h) will be randomized for treatment with APAP or fixed CPAP. Measurements of sympathetic activity by MSNA, heart rate variability and catecholamines will be obtained at baseline and after one month of treatment. The primary composite outcome will be the change in sympathetic tone measured by MSNA in bursts/min and bursts/100 heart beats. 

Ethics and dissemination: The protocol was approved by the Ethics Committee (*Comite de Protection des Personnes Sud Est V*) and was registered on ClinicalTrials.gov (NCT03428516).
 The study started in March 2018 with primary completion expected in March 2019.

49 26 Trial registration number: NCT03428516

Keywords: obstructive sleep apnea, hypertension, continuous positive airway pressure, sleep
medicine, sympathetic activity.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 4 of 32

BMJ Open

2 3	1	Strengths and limitations of the study:
4 5		
6	2	• The analysis of vascular and cardiac sympathetic activity will be evaluated by
7 8	3	complementary methods: microneurography of the peroneal nerve (the gold
9	4	standard method), heart rate variability (HRV) and urinary catecholamines.
10 11	5	• The use of 24h ambulatory blood pressure (BP) monitoring is more sensitive when
12	6	assessing therapeutic interventions than office BP and provides prognostic guidance.
13 14	7	<ul> <li>Subjects will be randomly allocated to one of the two positive airway pressure (PAP)</li> </ul>
15	,	subjects will be randomly anotated to one of the two positive an way pressure (FAF)
16 17	8	modalities by a statistician not involved in the data collection. All other investigators,
18	9	patients and assessment technicians will be blinded to the patient's group.
19 20	10	• The same make and model of CPAP device will be used both in Fixed and APAP
21	11	modes.
22 23	12	• The duration of exposure to treatment of one month is ample but might under-
24 25	13	represent the chronic effects of PAP therapies on sympathetic activity.
25 26		
27 28	14	
29	15	
30 31	15	
32	16	
33 34		
35	17	
36 37	18	
38		
39 40	19	
41 42	20	
43	20	
44 45	21	
46		
47 48	22	
49	23	
50 51	25	
52	24	
53 54		
55 56	25	
57		
58 59		4
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

#### BMJ Open

### **Introduction**

Obstructive sleep apnea (OSA) is associated with increased cardiovascular morbidity and mortality (1-6). Hypertension is a leading cause of death worldwide and the main factor implicated in cardiovascular risk (7-9). There is a dose-response relationship between indices of OSA severity and hypertension (10, 11). Accordingly, one of the most common objectives when treating OSA is blood pressure (BP) reduction in order to prevent or reduce late cardiovascular events.

Obstructive sleep apnea (OSA) is characterized by partial (hypopnea) or complete (apnea) upper airway collapses during sleep (12). Sympathetic activation is the main intermediary mechanism for BP elevation in OSA patients (11, 13). The repetitive occurrence of respiratory events leading to intermittent hypoxia and hypercapnia results in stimulation of central and peripheral chemoreflexes enhancing sympathetic activity and, subsequently increasing vascular tone and promoting blood pressure elevation (14). Chronic sympathetic activation induces vascular remodeling and, frequently, uncontrolled or resistant hypertension (15). In OSA patients, night-time sympathetic over-activation is associated with the non-dipping pattern of BP and the high sympathetic tone persists during wakefulness (16). In the early course of the disease, even non-hypertensive subjects exhibit increased BP and muscle sympathetic nerve activity in response to chronic intermittent hypoxia (13, 17).

Continuous positive airway pressure remains the gold standard therapeutic option for the treatment of severe OSA. Several systematic reviews and meta-analyses (18-24) have demonstrated limited but significant improvements in BP (a reduction of about 2 mmHg in 24-h mean BP). Better results are achieved in specific phenotypes with more severe OSA, higher BP at baseline and adherent to PAP therapies (use of CPAP  $\geq$  4 hours/night) (19, 25-27).

Auto-adjusting CPAP (APAP) changes the pressure delivered throughout the night depending on events detected, with the goal of applying the minimal effective pressure (28-31) thus reducing side effects and improving adherence. The average overnight applied pressure is significantly lower with APAP for the same range of improvement in the apneahypopnea index (AHI) (32). However, the continuous variations in pressure associated with the functioning of APAP devices potentially induce micro-arousals, and change sleep

macrostructure in some patients (31,33,34). This might limit the decrease in sympathetic activity during the night when treating OSA and consequently result in a smaller reduction of BP.

Studies have demonstrated controversial results on the impact of the two pressure modalities (fixed versus auto-adjusting) on blood pressure reduction (table 2). Although some authors reported superiority with fixed pressure (35, 36), other clinical trials reported no significant difference between APAP and CPAP (37-39). A recent study that evaluated 208 patients with a longer than usual follow up of 2 years demonstrated comparable reductions in sleepiness and blood pressure with similar OSA-related costs for both treatments (37). Karasulu et al (40) and Patruno et al (41) have demonstrated lower reduction in cardiac sympathetic activity using heart rate variability (HRV) in OSA patients and obese OSA patients during APAP treatment compared with fixed CPAP. However, neither study was randomized and Patruno evaluated only a specific population of obese patients with severe OSA, which limits the generalizability of the results. In a small study of adult males, without antihypertensive treatment, Marrone et al (34), evaluated BP changes after treatment with APAP versus CPAP. As a secondary outcome, they reported sympathetic activity by measurement of catecholamines. Norepinephrine decreased significantly after treatment in the APAP group but not in the CPAP group and normetanephrine decreased significantly in both groups. Overall, there is a lack of well-designed studies evaluating the mechanisms underlying specific BP responses under APAP versus fixed CPAP. In this context, the aim of the present study is to compare vascular sympathetic tone after one month of treatment with fixed versus auto-adjusting pressure by microneurography in newly diagnosed OSA patients.

#### 44 24 <u>Methods and analysis</u>

<u>Study design</u>

This study is a prospective, single-site, randomized, double-blind, parallel, one month-controlled trial.

28 <u>Objectives</u>

29 Primary research objective

 

1		
2 3	1	The main objective is to compare change in vascular sympathetic tone measured by
4 5	2	Muscle Sympathetic Nerve Activity (MSNA) microneurography after one month of APAP
6 7	3	versus after one month of fixed CPAP in treatment-naive moderate to severe OSA patients.
8 9	4	The primary composite outcome will be the change in sympathetic tone measured by
10	5	MSNA in bursts/min and bursts/100 heart beats between baseline and after one month of
11 12 13	6	treatment.
14 15	7	Secondary research objectives
16 17		
18	8	The secondary objectives will be to compare the following variables before and after
19 20	9	treatment:
20 21 22	10	- Ambulatory BP monitoring (24h ABPM): mean blood pressure (MBP), systolic blood
23	11	pressure (SBP) and diastolic blood pressure DBP, during 24h periods as well as daytime and
24 25	12	night-time measurements.
26 27		
27 28	13	- Urinary catecholamines (24h collection): epinephrine, norepinephrine, and dopamine.
29 30	14	- Heart Rate Variability as an indicator of cardiac sympathovagal balance.
31 32		
33 34	15	<u>Population</u>
35	16	Consecutive adult outpatients attending a tertiary hospital sleep center (Grenoble
36 37	17	Alpes University Hospital – France), with an established diagnosis of obstructive sleep apnea
38 39	18	by full-night polysomnography (apnea-hypopnea index > 20/hour), and willing to receive
40	19	positive airway pressure treatment, will be enrolled in the study. The inclusion and exclusion
41 42	20	criteria are presented in table 1. Written informed consent will be obtained from all
43 44	21	participants by a sleep physician study investigator (supplementary file).
45 46	22	Materials
47 48		
49 50	23	Muscle Sympathetic Nerve Activity (MSNA)
50 51 52	24	Multiunit postganglionic muscle sympathetic activity will be recorded from the
52 53	25	peroneal nerve (Figure 1). A reference electrode and a collecting electrode will be inserted
54 55	26	percutaneously to record the discharges of the muscle sympathetic fibres contained in the
56	27	peroneal nerve. Dorsiflexion of the first toe will confirm the correct placement of the
57 58		7

electrode. Neural activity will be amplified, band-pass filtered, rectified and integrated to
 create a sympathetic neurogram for real-time inspection. The raw, unfiltered neurogram will
 be recorded at 40 kHz for processing using our algorithm for identification of sympathetic
 nerve signals (42). All signals will be digitized and stored (Windaq, DATAQ Instruments, or
 PowerLab, ADInstruments) for subsequent analysis.

MSNA will be expressed as burst frequency (bursts·min<sup>-1</sup>) and burst frequency
 normalized to heart beat (bursts per 100 beats).

8 During the measurement of MSNA, a standard 3-lead electrocardiogram will 9 continuously record heart rate. Beat-by-beat arterial BP will be non-invasively measured 10 throughout the study session via finger photoplethysmography (CNAP 500, CNSystems, 11 Austria) and calibrated against oscillometric brachial pressure.

<u>Blood flow</u>

Popliteal blood velocity will be recorded using a 4-MHz Doppler probe (Multidop T2, DWL) at the popliteal fossa of the contralateral leg to the sympathetic nerve recording.

Several parameters will be extracted from the above measurements: sympathetic vascular tone, blood pressure and blood flow. Furthermore, we shall calculate vascular resistance and vascular sympathetic tone and blood pressure gains, as previously described (14, 43).

#### <u>Blood Pressure</u>

Ambulatory BP monitoring (ABPM) will use Spacelabs 90207<sup>®</sup> devices (Spacelabs International, Redmond, Washington, USA). The measurements will be made using an oscillometric method and programmed every 15 minutes during the day and every 30 minutes at night. The following ABPM parameters will be studied: mean SBP, mean DBP and mean HR over 24 hours, the same mean values during the daytime (7.00 am to 10.00 pm) and at night-time (10.00 pm to 7.00 am). The normal night-time physiological dipping BP is expected to be > 10%. The summary values in the ABPM report for each patient will be used in the data analysis. This is an average by subject and by recording session (at baseline and 1 month). Data relating to the average daytime and night-time systolic BP (SBP), diastolic BP (DBP), and mean BP (MBP) will be recorded. SBP values of > 260 mmHg or < 70 mmHg and 

Page 9 of 32

2 3	1	DBP > 150 mmHg or < 40 mmHg will be automatically eliminated. Daytime hypertension is
4	2	defined as daytime SBP > 135 mmHg and/or DBP > 85 mmHg, and night-time hypertension
5 6	3	as SBP > 120 mmHg and/or DBP > 70 mmHg
7	5	
9	4	Clinical BPs (SBP and DBP) will be measured by mercury sphygmomanometer on
10 11	5	three occasions in line with the European Society of Hypertension-European Society of
12 13	6	Cardiology and American College of Cardiology/ American Heart Association guidelines (9,
13 14 15	7	44). Mean arterial BP (MABP) will be calculated as DBP + 1/3(SBP-DBP).
15 16 17	8	Each recording will be validated only if the following quality criteria are met: cuff size
18	9	adapted to the diameter of the arm, calibration of the device, full 24 hours' duration of
19 20	10	recording comprising at least 48 valid measures and no more than two missing time slots.
21		
22 23	11	Catecholamine measurements
24	10	24h uring complex will be collected peridified with pratic perid and stored at 20°C until
25 26	12	24ii unite samples will be collected, actumed with acetic actuality stored at -20 C unit
27 28	13	analysis. Catecnolamines (epinephrine, norepinephrine, and dopamine) will be measured in
29	14	one millilitre of urine by high-performance liquid chromatography with electrochemical
30 31	15	detection (Coularray Detector, ESA Dionex, Chelmsford, USA).
32	16	Polysomnoaraphy
33 34		
35	17	Full night polysomnography will be performed at our sleep laboratory. The following
30 37	18	physiological variables will be monitored: electroencephalography (EEG), electrooculography
38 39	19	(EOG), electromyography (EMG), electrocardiography (ECG), oral and nasal airflows, chest
40	20	and abdominal respiratory effort through inductance plethysmography, snoring, body
41 42	21	position, oxyhemoglobin saturation by pulse oximetry and heart rate. Continuous recordings
43 44	22	will be taken with electrode positions C3/A2-C4/A1-Cz/01 of the international 10-20
45 46	23	Electrode Placement System, along with eye movements, chin electromyogram and ECG
47	24	with a modified V2 lead. Airflow will be measured with nasal pressure prongs together with
48 49	25	the sum of oral and nasal thermistor signals. Respiratory effort will be monitored using
50 51	26	abdominal and thoracic bands. Oxygen saturation will be measured using a pulse oximeter.
52 53	27	Respiratory events will be classified according to the American Academy of Sleep Medicine's
54	28	guidelines (45). An apnea is defined as the complete cessation of airflow for at least 10
55 56	20	encode and human and a standard and a first locat 200/ in the proof processing size of a standard
	29	seconds and hypophea as a reduction of at least 30% in the hasal pressure signal associated

with either oxygen desaturation of ≥3% or an EEG arousal from sleep, both lasting for at
 least 10 seconds. Apneas will be classified as obstructive, central or mixed according to the
 presence or absence of respiratory effort. The classification of hypopneas as obstructive or
 central will be based on the thoraco-abdominal band signal and the shape of the nasal
 respiratory pressure curve (flow limited aspect or not). The AHI is defined as the number of
 apneas and hypopneas per hour of sleep. Sleep will be scored manually according to AASM
 criteria (45).

#### <u>Procedures</u>

At the baseline visit, MSNA, ABPM, calf blood flow, HRV and catecholamines will be measured. Then, during a one week titration phase optimal CPAP pressure will be obtained over eight nights at home using an auto CPAP device (RESMED<sup>™</sup>) to obtain a fixed CPAP pressure value. The optimal pressure (95th percentile) will be determined by one expert researcher, based on visual evaluation of the raw data recordings from nights with no significant leaks. A minimum of continuous pressure use for 4 hours per night will be required. The pressure determined during the titration nights will be used as the therapeutic pressure in the fixed CPAP mode, whereas in APAP the pressure level will be adjusted between a minimal pressure of 6 cmH<sub>2</sub>O and a maximum of 16 cmH<sub>2</sub>O. After the titration phase, patients will be randomized to treatment with either APAP or fixed CPAP. Finally, following one month of treatment, MSNA, ABPM, calf blood flow, HRV and catecholamines will be measured for comparison with baseline. Figure 2 shows the study schema.

- 21 <u>Statistical considerations</u>
  - <u>Sample size</u>

We powered the study based on the MSNA outcome. To date no previous study has compared these two PAP modalities using MSNA as primary outcome. Since there are no reliable MSNA data available, we hypothesized the impact of CPAP to be 8±5 bursts/min in the fixed CPAP group and 5±5 bursts/min in the APAP group. Assuming an alpha error of 5%, a statistical power of 80%, in unilateral situation, 34 patients per arm will need to be enrolled in the study. Page 11 of 32

#### BMJ Open

In a group sequential design, firstly an interim analysis will be performed on data
from the first 24 patients (12 per arm) with a nominal p value of 0.0081 required to
demonstrate a significant difference between groups. If at the interim analysis, the observed
p value for the primary outcome is greater than the nominal p value inclusions will continue
until the final sample of 68 patients is reached. Conversely, if significance is observed, the
patient inclusion can stop and no further inclusions will be needed.

#### <u>Randomization</u>

After titration of fixed CPAP (lasting 8 nights), patients will be randomized to either fixed CPAP or APAP treatment. Randomization will be conducted by a statistician independent of the study using a computer-generated random numbers list (6 patients per block). This list will be transmitted to one of the investigators who will be responsible for installation of the device but not for the follow-up and evaluation of the patients. All other investigators, patients and outcome assessment technicians will be masked to the patient's group.

15 <u>Statistical methodology and analyses</u>

The analysis will be done following the Intention to treat method. Continuous variables will be expressed as median (25th/75th percentiles) or mean (SD), while categorical variables will be reported as absolute numbers and percentages for both groups. Baseline comparisons between groups will be made using a Student test or Mann-Whitney test, depending on validation of normal distribution. For discrete variables, a Chi-square test will be used. Normality will be assessed using the Shapiro-Wilk test. If significant differences are observed between arms, a multivariable regression will be performed. In case of missing data, an imputation strategy will be applied according to the percentage of missing values. If less than 5% of missing value are observed, simple imputation will be performed, based on the median for quantitative variables or on the most frequent values for qualitative variables. If the proportion of missing values is between 5 and 20%, multiple imputations will be performed.

Data management and statistical analyses will be performed using SAS<sup>®</sup> (version 9.4, SAS Institute, Cary, NC, USA).

#### <u>Ethics</u>

The current study will be conducted in accordance with the Declaration of Helsinki and the recommendations for Good Clinical Practice. The protocol was approved by the French Regional Ethics Committee (Comite de Protection des Personnes Sud Est V N<sup>o</sup> IRB: 0006705 on 19 February 2018). Written informed consent will be signed by all study participants before enrollment in the study. Patients have the right to withdraw from the study without incurring any prejudice at any time. The protocol is registered on the ClinicalTrials.gov website (NCT03428516).

Patient and Public Involvement

Patients, collaborators and sponsors were not directly involved in the design, recruitment and conduction of the study. Dissemination plans of the results include presentations at conferences and publication in peer-reviewed journals. Updates of the randomized trial will be available at ClinicalTrials.com. All patients will be informed that the dissemination of results will be accessible on request.

#### Sponsor and funding

The sponsor of the study is Grenoble Alpes University Hospital, France. The principal investigator is Renaud Tamisier. Erika Treptow is supported by the *Coordenação de Aperfeiçoamento de Pessoal de Nível Superior* (CAPES) – Brazil. ResMed, *"Agir pour les maladies chroniques"* and the French National Research Agency in the framework of the "Investissements d'avenir" program (ANR-15-IDEX-02) will provide unrestricted funding. The collaborators and sponsors were not involved in the design of the study and will not influence the execution, analysis and publication of results.

#### **BMJ** Open

### **Discussion**

CPAP remains the first-line therapy for OSA patients. In order to determine the optimal pressure that will maintain airway patency during sleep, a titration made during full night polysomnography is required. However, this is costly, demands technical expertise and may result in a delay in the initiation of treatment. Furthermore, night-time AHI can be variable, depending on position, sleep architecture, overnight rostral fluid shifts and alcohol intake, which may influence the determination of the optimal effective pressure if performed during only one night (46, 47). Therefore, over the last few years there has been an exponential increase of the use of APAP for automatic titration prior to long-term treatment at home. This simplified procedure is associated with comparable outcomes (48) and a significant cost reduction (49). 

Currently, in many countries especially in Europe, APAP is by far the most commonly used device for OSA treatment and gives a slight increase in PAP adherence (50). However, the increase in APAP use is accompanied by unresolved scientific questions: is APAP as effective as fixed CPAP in reducing cardiovascular risk? Is it safe to use APAP in patients with comorbidities? Do APAP and CPAP have the same efficacy in normalizing sleep in patients with OSA? The proposed study will focus on the cardiovascular response to these different PAP modalities. To achieve this, we shall use complementary reference tools to evaluate sympathetic activity in patients using fixed CPAP or APAP. Vascular and cardiac sympathetic activity will be explored in addition to circulating catecholamine levels. 

Since its first description in 1967 (51) vascular sympathetic activity measured by microneurography has provided insights into our understanding of the pathophysiology of hypertension, cardiac failure and sleep apnea (16, 52). This method allows the recording of impulses in peripheral nerves and is the gold standard for measurement of vascular sympathetic activity. When applied by experienced professionals, MSNA is reproducible and allows evaluation between subjects before and after an intervention, with minor risks and side effects (43, 53). It has been demonstrated that intermittent hypoxia is a major contributor to inducing sympathetic activation in healthy humans and patients with OSA (13, 17, 54) and that treatment with CPAP lowers MSNA (55). One of the strengths of the present study is that, in addition to MSNA, we will measure heart rate variability and urinary catecholamines to assess cardiac and whole body sympathetic activity respectively. 

Moreover, we will provide a better understanding of BP responses under the two PAP therapies and possibly identify the type of patients who would benefit the most from APAP. **Conclusions** The sympathetic APAP-CPAP protocol is key randomized controlled trial that will assess, for the first time, different PAP modalities that might differ in terms of the decrease in sympathetic activity they induce in patients with OSA. The results of the APAP-CPAP study should provide further clarification as to the cardiovascular benefits of an effective treatment for patients with OSA. In addition, the findings might have important implications for individualized therapeutic strategies by identifying the best phenotypes to be treated by a given PAP therapy. Author contributions ET participated in the design of the study, wrote the article based on the study protocol, will include patients, and collect and analyze data into the protocol. JLP and PL designed the study, wrote the study protocol, critically revised the manuscript and will include patients into the protocol. SB participated in the design of the protocol, established the statistical analysis plan, and calculated the sample size. CB revised the manuscript and will include patients into the protocol. MD revised the manuscript and will include patients into the protocol. HW participated in the design of the study and critically revised the manuscript. RT designed the study, wrote the study protocol and article, critically revised the manuscript and will include patients, and collect and analyze data. The submitted manuscript has been approved by all authors. **Acknowledgements** The authors would like to thank Marie Peeters for trial management and Alison Foote (Grenoble Alpes University Hospital, Research division) for language revision. Funding 

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1		
2 3	1	ET is supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
4 5	2	(CAPES) – Brazil. This work was supported by unrestricted grant from ResMed, by the
6	3	foundation Agir pour les maladies chroniques and by the French National Research Agency in
/ 8	4	the framework of the "Investissements d'avenir" program (ANR-15-IDEX-02).
9 10		
11	5	<u>Competing interests</u>
12 13	6	R Tamisier reports travel grants from Agiradom (a Home Healthcare provider) and
14 15	7	research grants from Resmed.
16	8	
17 18	9	Ethics approval
19 20		
21	10	The protocol was approved by the French Regional Ethics Committee (Comite de
22 23	11	Protection des Personnes Sud Est V) on 19 February 2018 and is registered on
24 25	12	ClinicalTrials.gov (NCT03428516).
26	13	
27 28	14	Patient consent
29 30	15	Written informed consent will be signed by all study participants before enrollment
31	16	in the study (see supplement materials).
32 33	17	
34 35	18	
36 27	19	
38	20	
39 40	21	
41 42	22	
43	23	
44 45	24	
46 47		
48		
49 50		
51 52		
53		
54 55		
56 57		
58		15
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

|--|

Table 1. Inclusion and exclusion criteria

	Inclusion criteria	Exclusion criteria
	Patients aged 18 to 80 years	Pregnancy
	OSA (AHI ≥20 events/ h)	Person deprived of liberty or subject to a
		legal protection measure.
	Daytime sleepiness	Patient with heart failure
	Naive of any pressure treatment for OSA	Patient with central sleep apnea index above
		20% of AHI
	Able to provide written informed consent	Patient with unstable comorbidities that
		could influence the results
	Not a vulnerable person or legally protected	d
	adult	
3		
4	OSA, obstructive sleep apnea; AHI, apnea hy	rpopnea index
5		
-		
6		
7		
8		
0		
9		
10		
11		
12		
13		
14		
45		
12		
		16
	For peer review only - http://bmJop	en.bmj.com/site/about/guidelines.xntml

### Table 2. Literature on the impact of CPAP versus APAP on BP

Author	Year	Sample	Study design	Duration	Intervention	Findings
(ref.)		Size				
Bloch KE	2017	208	Randomized,	2 years	APAP (5-15 cmH <sub>2</sub> O) vs CPAP (90 <sup>th</sup> percentile during titration)	Reduction in MBP, SBP and DBP by 3-4 mmHg (ITT) and 4-6 mmHg (PPT),
	2016	222	Paralensiand	4 we are the	ADAD (minimal internal of 5 amil 0)	Shinidi ili AFAF X CFAF
(35)	2016	322	parallel	4 months	vs CPAP (95 <sup>th</sup> percentile during	CPAP was more effective in reducing 24n DBP than APAP * 1
					titration)	
Marrone O	2011	17	Randomized,	2 months	APAP (5-18 cmH $_2$ O) vs CPAP (fixed	Treatment reduced SBP during sleep and DBP during both sleep and
(38)			parallel		pressure determined during	wakefulness. Similar reductions in BP were demonstrated in both groups $\ensuremath{^*}$
					titration)	
Patruno V	2007	31	Randomized,	3 months	APAP (4-15 cmH <sub>2</sub> O) vs CPAP (fixed	Significant reduction in SBP (from 144 $\pm$ 10 to 132 $\pm$ 8 mm Hg; p < 0.001)
(36)			parallel		pressure determined during	and DBP (from 88 $\pm$ 4 to 79 $\pm$ 6 mmHg; p < 0.001) in the CPAP group but not
					titration)	in the APAP group (SBP, 142 ± 12 to 136 ± 6 mm Hg; DBP, 87.5 ± 4 to 86 ± 4
						mm Hg) †
West SD	2006	98	Randomized,	6 months	APAP vs APAP for 1 week and then	No difference between groups in MBP *
(39)			parallel		CPAP (95 <sup>th</sup> percentile during	
					titration)or CPAP (determined by	
					an algorithm)	

CPAP, continuous positive pressure; APAP, auto-adjusting continuous positive pressure; BP, blood pressure; MBP, mean blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; ITT, intention-to-treat analysis; PPT, per protocol analysis.

\* Ambulatory Blood Pressure Monitoring (24h) + Office blood pressure measurements.

## 1 Figure legend

Figure 1. Settings, acquisition, recording and reporting of muscle sympathetic nerve activity (MSNA). Measurement of MSNA is obtained by placement of an un-insulated tungsten register electrode in the peroneal nerve in the popliteal fossae or close to the fibula head. The objective is to reach post ganglionic efferent sympathetic neurons. Potential voltage signal is recorded between the nerve electrode and a reference electrode placed on the external side of the knee. The acquired electrical signal is then amplified, band-filtered (700 to 2000 Hz), rectified and integrated. Sympathetic burst, which correspond to nerve firing, are detected and scored using an automatic software in order to minimize subjective interpretation of the signal MSNA results may be expressed in number of bursts per min or per 100 heart beats, Burst/min and bursts/100 hb respectively or using the sum of areas under the curve of all burst in arbitrary integration units per minute or per 100 heart beats, AUI/min and AUI/100 hb respectively.

Figure 2. Study protocol

MSNA, Muscle Sympathetic Nerve Activity; HRV, heart rate variability; CPAP, fixed continuous positive pressure; APAP, auto-adjusting continuous positive pressure.

1		
2		
3	1	
4		
5	2	<u>References</u>
6 7		
/ 8	3	1. Baguet JP, Barone-Rochette G, Tamisjer R, Levy P, Pepin JL, Mechanisms of cardiac
9	4	dysfunction in obstructive sleep apnea. Nature reviews Cardiology. 2012;9(12):679-88.
10	5	2. Yaggi HK. Concato J. Kernan WN. Lichtman JH. Brass LM. Mohsenin V. Obstructive sleep
11	6	apprea as a risk factor for stroke and death. The New England journal of medicine.
12	7	2005:353(19):2034-41.
13	8	3. Gami AS. Olson Ei Fau - Shen WK. Shen Wk Fau - Wright RS. Wright Rs Fau - Ballman KV.
14	9	Ballman Ky Fau - Hodge DO, Hodge Do Fau - Herges RM, et al. Obstructive sleep apnea and the risk of
15	10	sudden cardiac death: a longitudinal study of 10,701 adults. (1558-3597 (Electronic)).
16	11	4. Sundstrom J, Neal B. Effects of Blood Pressure Reduction in Mild Hypertension. Annals of
17	12	internal medicine. 2015;163(1):67-8.
18	13	5. Drager LF, McEvoy RD, Barbe F, Lorenzi-Filho G, Redline S, Initiative I. Sleep Apnea and
19	14	Cardiovascular Disease: Lessons From Recent Trials and Need for Team Science. Circulation.
20	15	2017;136(19):1840-50.
21	16	6. Javaheri S, Barbe F, Campos-Rodriguez F, Dempsey JA, Khayat R, Javaheri S, et al. Sleep
22	17	Apnea: Types, Mechanisms, and Clinical Cardiovascular Consequences. J Am Coll Cardiol.
23	18	2017;69(7):841-58.
24 25	19	7. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk
25	20	assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in
20	21	21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet.
27	22	2012;380(9859):2224-60.
20	23	8. Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Cowan MJ, et al. National, regional,
30	24	and global trends in systolic blood pressure since 1980: systematic analysis of health examination
31	25	surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet.
32	26	2011;377(9765):568-77.
33	27	9. Whelton Pk Fau - Carey RM, Carey Rm Fau - Aronow WS, Aronow WS, Casey DE, Jr., Collins KJ,
34	28	Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA
35	29	Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in
36	30	Adults: A Report of the American College of Cardiology/American Heart Association Task Force on
37	31	Clinical Practice Guidelines. LID - HYP.0000000000000065 [pii] LID - 10.1161/HYP.000000000000065
38	32	[doi] FAU - Whelton, Paul K. (1524-4563 (Electronic)).
39	33	10. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-
40	34	disordered breathing and hypertension. The New England journal of medicine. 2000;342(19):1378-
41	35	84.
42	36	11. Narkiewicz K, Somers VK. Obstructive sleep apnea as a cause of neurogenic hypertension.
43 44	37	Current hypertension reports. 1999;1(3):268-73.
44 15	38	12. Levy P, Kohler M, McNicholas WT, Barbe F, McEvoy RD, Somers VK, et al. Obstructive sleep
46	39	apnoea syndrome. Nature reviews Disease primers. 2015;1:15015.
47	40	13. Tamisier R, Pepin JL, Remy J, Baguet JP, Taylor JA, Weiss JW, et al. 14 nights of intermittent
48	41	hypoxia elevate daytime blood pressure and sympathetic activity in healthy humans. The European
49	42	respiratory journal. 2011;37(1):119-28.
50	43	14. Tamisier R, Tan CO, Pepin JL, Levy P, Taylor JA. Blood Pressure Increases in OSA due to
51	44	Maintained Neurovascular Sympathetic Transduction: Impact of CPAP. Sleep. 2015;38(12):1973-80.
52	45	15. Tamisier R, Levy P, Pepin JL. Do patients with obstructive sleep apnoea deserve new
53	46	dedicated antihypertensive strategies? Thorax. 2017;72(6):495-7.
54	47	16. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive
55	48	sleep apnea. The Journal of clinical investigation. 1995;96(4):1897-904.
56		
57		
58		19
59		For near review only - http://bmionen.hmi.com/site/about/guidalings.yhtml
60		i or peer review only - nttp.//binjopen.binj.com/site/about/guidennes.xhtml

17. Gilmartin GS, Lynch M, Tamisier R, Weiss JW. Chronic intermittent hypoxia in humans during 28 nights results in blood pressure elevation and increased muscle sympathetic nerve activity. American journal of physiology Heart and circulatory physiology. 2010;299(3):H925-31. Bratton DJ, Gaisl T, Wons AM, Kohler M. CPAP vs Mandibular Advancement Devices and 18. Blood Pressure in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta-analysis. Jama. 2015;314(21):2280-93. 19. Bratton DJ, Stradling JR, Barbe F, Kohler M. Effect of CPAP on blood pressure in patients with minimally symptomatic obstructive sleep apnoea: a meta-analysis using individual patient data from four randomised controlled trials. Thorax. 2014;69(12):1128-35. 20. Montesi SB, Edwards Ba Fau - Malhotra A, Malhotra A Fau - Bakker JP, Bakker JP. The effect of continuous positive airway pressure treatment on blood pressure: a systematic review and meta-analysis of randomized controlled trials. (1550-9397 (Electronic)). 21. Alajmi M, Mulgrew At Fau - Fox J, Fox J Fau - Davidson W, Davidson W Fau - Schulzer M, Schulzer M Fau - Mak E, Mak E Fau - Ryan CF, et al. Impact of continuous positive airway pressure therapy on blood pressure in patients with obstructive sleep apnea hypopnea: a meta-analysis of randomized controlled trials. (0341-2040 (Print)). Bazzano LA, Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive airway 22. pressure on blood pressure in obstructive sleep apnea. Hypertension. 2007;50(2):417-23. 23. Haentjens P, Van Meerhaeghe A Fau - Moscariello A, Moscariello A Fau - De Weerdt S, De Weerdt S Fau - Poppe K, Poppe K Fau - Dupont A, Dupont A Fau - Velkeniers B, et al. The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-controlled randomized trials. (0003-9926 (Print)). 24. McDaid C, Duree KH, Griffin SC, Weatherly HL, Stradling JR, Davies RJ, et al. A systematic review of continuous positive airway pressure for obstructive sleep apnoea-hypopnoea syndrome. Sleep medicine reviews. 2009;13(6):427-36. 25. Martinez-Garcia MA, Capote F, Campos-Rodriguez F, Lloberes P, Diaz de Atauri MJ, Somoza M, et al. Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial. Jama. 2013;310(22):2407-15. 26. Barbe F, Duran-Cantolla J, Sanchez-de-la-Torre M, Martinez-Alonso M, Carmona C, Barcelo A, et al. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. Jama. 2012;307(20):2161-8. 27. Pepin JL, Timsit JF, Tamisier R, Levy P. Is CPAP effective in reducing blood pressure in minimally symptomatic obstructive sleep apnoea? Thorax. 2014;69(12):1068-70. Sanders MH, Montserrat JM, Farre R, Givelber RJ. Positive pressure therapy: a perspective on evidence-based outcomes and methods of application. Proceedings of the American Thoracic Society. 2008;5(2):161-72. Hertegonne K, Bauters F. The value of auto-adjustable CPAP devices in pressure titration and 29. treatment of patients with obstructive sleep apnea syndrome. Sleep medicine reviews. 2010;14(2):115-9. 30. Morgenthaler TI, Aurora RN, Brown T, Zak R, Alessi C, Boehlecke B, et al. Practice parameters for the use of autotitrating continuous positive airway pressure devices for titrating pressures and treating adult patients with obstructive sleep apnea syndrome: an update for 2007. An American Academy of Sleep Medicine report. Sleep. 2008;31(1):141-7. 31. Won CH. Man Versus Machine. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2017;13(2):167-8. Ayas NT, Patel SR, Malhotra A, Schulzer M, Malhotra M, Jung D, et al. Auto-titrating versus 32. standard continuous positive airway pressure for the treatment of obstructive sleep apnea: results of a meta-analysis. Sleep. 2004;27(2):249-53. 

2		
3	1	33. Fuchs FS, Wiest GH, Frank M, Harsch IA, Schahin SP, Hahn EG, et al. Auto-CPAP therapy for
4	2	obstructive sleep apnea: induction of microarousals by automatic variations of CPAP pressure? Sleep.
5	3	2002;25(5):514-8.
6	4	34. Marrone O, Insalaco G, Bonsignore MR, Romano S, Salvaggio A, Bonsignore G. Sleep structure
7	5	correlates of continuous positive airway pressure variations during application of an autotitrating
8	6	continuous positive airway pressure machine in patients with obstructive sleep apnea syndrome.
9	7	Chest. 2002;121(3):759-67.
10	8	35. Pepin JL, Tamisier R, Baguet JP, Lepaulle B, Arbib F, Arnol N, et al. Fixed-pressure CPAP versus
11	9	auto-adjusting CPAP: comparison of efficacy on blood pressure in obstructive sleep apnoea, a
12	10	randomised clinical trial. Thorax. 2016;71(8):726-33.
13	11	36. Patruno V, Aiolfi S, Costantino G, Murgia R, Selmi C, Malliani A, et al. Fixed and autoadjusting
14	12	continuous positive airway pressure treatments are not similar in reducing cardiovascular risk factors
15	13	in patients with obstructive sleep apnea. Chest. 2007;131(5):1393-9.
10	14	37. Bloch KE, Huber F, Furian M, Latshang TD, Lo Cascio CM, Nussbaumer-Ochsner Y, et al.
17 10	15	Autoadjusted versus fixed CPAP for obstructive sleep apnoea: a multicentre, randomised equivalence
10	16	trial. Thorax. 2017.
20	17	38. Marrone O, Salvaggio A, Bue AL, Bonanno A, Riccobono L, Insalaco G, et al. Blood pressure
20	18	changes after automatic and fixed CPAP in obstructive sleep apnea: relationship with nocturnal
21	19	sympathetic activity. Clinical and experimental hypertension. 2011;33(6):373-80.
23	20	39. West SD, Jones DR, Stradling JR. Comparison of three ways to determine and deliver pressure
24	21	during nasal CPAP therapy for obstructive sleep apnoea. Thorax. 2006;61(3):226-31.
25	22	40. Karasulu L, Epozturk PO, Sokucu SN, Dalar L, Altin S. Improving Heart rate variability in sleep
26	23	apnea patients: differences in treatment with auto-titrating positive airway pressure (APAP) versus
27	24	conventional CPAP. Lung. 2010;188(4):315-20.
28	25	41. Patruno V, Tobaldini E, Bianchi AM, Mendez MO, Coletti O, Costantino G, et al. Acute effects
29	26	of autoadjusting and fixed continuous positive airway pressure treatments on cardiorespiratory
30	27	coupling in obese patients with obstructive sleep apnea. European journal of internal medicine.
31	28	2014:25(2):164-8.
32	29	42. Hamner JW. Taylor JA. Automated quantification of sympathetic beat-by-beat activity.
33	30	independent of signal quality. Journal of applied physiology 2001;91(3):1199-206
34	31	43 Tan CO Tamisier R Hamner IW Taylor IA Characterizing sympathetic neurovascular
35	32	transduction in humans. PloS one 2013;8(1):e53769
36	32	44 Mancia G. De Backer G. Dominiczak A. Cifkova R. Fagard R. Germano G. et al. 2007 Guidelines
37	34	for the Management of Arterial Hypertension: The Task Force for the Management of Arterial
38	35	Hypertension of the European Society of Hypertension (ESH) and of the European Society of
39	36	Cardiology (ESC) Journal of hypertension 2007:25(6):1105-87
40	37	45 Berry RB Brooks R Gamaldo C Harding SM Lloyd RM Quan SE et al AASM Scoring Manual
41	38	Lindates for 2017 (Version 2.4) Journal of clinical sleen medicine - ICSM - official publication of the
42	30	American Academy of Sleen Medicine, 2017:13(5):665-6
43	10	American Academy of Sicep Medicine, 2017,15(5),005 0. A Monte I H. Lyons OD. Vadollabi A. Ryan CM. Bradley TD. Night-to-night variability in
44 45	40	obstructive sleep appeal severity: relationship to overnight rostral fluid shift. Journal of clinical sleep
45 46	41	medicine : ICSM : official nublication of the American Academy of Sleen Medicine 2015:11(2):149-
40 47	42	
47 70	45	30. 47 Bittoncourt I.B. Suchacki D. Tufik S. Daros C. Tagaira SM. Pagnata MC. at al. The variability of
40 40	44	the approve hyperprese index. Journal of clean research 2001:10(2):245-51
50	45	As a Stradling IP. Parbour C. Ditcon DL. Davies PL. Automatic pasal continuous positive airway
51	40	46. Strading JK, Barbour C, Pitson DJ, Davies KJ. Automatic hasar continuous positive an way
52	47	pressure infation in the laboratory, patient outcomes. morax. 1997,52(1).72-5.
53	48	49. Corrar J, Sanchez-Quiroga MA, Carmona-Bernai C, Sanchez-Armengol A, de la Torre AS,
54	49	Duran-Cantona J, et al. Conventional Polysonnography is Not Necessary for the Management of
55	50	Most Patients with Suspected Obstructive Sleep Apnea. Noninferiority, Randomized Controlled Trial.
56	51	American journal of respiratory and critical care medicine. 2017;196(9):1181-90.
57		
58		21
59		21
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1		
2		
3	1	50. Smith I, Nadig V, Lasserson IJ. Educational, supportive and behavioural interventions to
4	2	improve usage of continuous positive airway pressure machines for adults with obstructive sleep
5	3	aphoea. Cochrane Database Syst Rev. 2009(2):CD007736.
6	4	51. Vallbo AB, Hagbarth KE. Impulses recorded with micro-electrodes in human muscle nerves
/	5	during stimulation of mechanoreceptors and voluntary contractions. Electroencephalogr Clin
8	6	Neurophysiol. 1967;23(4):392.
9 10	/	52. Mark AL, Wallin BG. Microneurography: a technique for assessing central neural effects of
10	8	adrenergic drugs on sympathetic outflow in humans. Journal of cardiovascular pharmacology. 1985;7
12	9	Suppl 8:567-9.
12	10	53. Kimmerly DS, O'Leary DD, Shoemaker JK. Test-retest repeatability of muscle sympathetic
14	11	nerve activity: influence of data analysis and head-up tilt. Auton Neurosci. 2004;114(1-2):61-/1.
15	12	54. Xie A, Skatrud JB, Crabtree DC, Puleo DS, Goodman BM, Morgan BJ. Neurocirculatory
16	13	consequences of intermittent asphysia in humans. Journal of applied physiology. 2000;89(4):1333-9.
17	14	55. Narkiewicz K, Kato M, Phillips BG, Pesek CA, Davison DE, Somers VK. Nocturnal continuous
18	15	positive airway pressure decreases daytime sympathetic traffic in obstructive sleep apnea.
19	16	Circulation. 1999;100(23):2332-5.
20	17	
21	17	
22		
23	18	
24		
25		
26		
27		
28		
29		
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
45 11		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
50 57		
57 59		
JÖ		22

59

1		
2 3	1	Supplementary file
4 5 6	2	Patient consent forms: French and English versions.
7 8 9	3	
10 11	4	
12 13 14	5	
15 16		
17 18 19		
20 21		
22 23		
24 25 26		
20 27 28		
29 30		
31 32		
33 34 35		
36 37		
38 39		
40 41 42		
42 43 44		
45 46		
47 48		
49 50 51		
52 53		
54 55		
56 57		
58 59		For poor rouiou, only http://bmienor.htmi com/site/sheut/suid-lin
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines

1		
2 3	1	Supplementary material – Consent form (original French version)
4 5		<u>`</u>
6	2	FORMULAIRE DE CONSENTEMENT ECLAIRÉ
7 8		
9	3	Diminution du tonus sympathique chez les patients avec une apnée obstructive du
10 11	4	sommeil: La CPP fixe est-elle plus efficace que la CPP auto aiusté?
12		
13 14	5	Titre court : APAP CPAP
15 16	c	
17	0	
18 19	7	
20		
21 22	8	<u>Promoteur de l'étude</u> : CHU de Grenoble – DRCI (Direction de la Recherche Clinique et
23	9	Innovation) : CHU de Grenoble, CS 10217, 38043 Grenoble Cedex 09 - Tel : 04 76 76 56 09
24 25	10	Fax : 04 76 76 52 21
26 27	11	Investigateur principal - Pr. Repaud Tamicier
28	11	investigateur principat. Pr. Kenaud Parinsier
29 30	12	Investigateurs du CHU de Grenoble participant à cette étude :
31		
32 33	13	Pr Jean-Louis Pépin, Pr Renaud Tamisier, Pr Patrick Levy, Dr Marie Destors, Dr Erika Treptow,
34 25	14	Dr. Holger Whorle: Physiologie Sommeil et Exercice - Pôle Locomotion Rééducation et
35 36	15	Physiologie; Dr Cecile Bosc : Centre Santé et Sommeil.
37 38	16	
39	17	Le Dr à l'étude APAP CPAP. Il m'a proposé de participer à l'étude APAP CPAP. Il m'a
40 41	18	expliqué en détail les objectifs et le déroulement de celle-ci, ainsi que les bénéfices, les
42 43	19	risques et les contraintes.
43 44		
45 46	20	Une notice d'information m'a été remise et j'ai eu suffisamment de temps pour la lire et
47	21	prendre la décision d'accepter ou non de participer à l'étude. J'ai pu poser toutes les
48 49	22	questions que je souhaitais et j'ai obtenu des réponses satisfaisantes. J'ai bien compris que
50 51	23	ma participation à l'étude est volontaire et que je peux à tout moment retirer mon
52	24	consentement, quelles que soient mes raisons, sans engager ma responsabilité et sans que
53 54	25	cela modifie la qualité des soins qui me seront donnés, ni l'attention de mon médecin.
55 56	26	
57	20	
58 59		24
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

60

2		
3	1	J'ai bien pris connaissance que cette recherche sera conduite en conformité avec le Code de
4 5	2	la Santé Publique.
6		
/ 8	3	
9	4	J'ai eu l'assurance que les décisions qui s'imposent pour ma santé seront prises à tout
10 11	5	moment, conformément à l'état actuel des connaissances médicales.
12 13	6	
14	7	J'ai compris que je ne dois pas participer à une autre recherche en même temps que celle-ci.
15 16 17	8	
18	9	En cours d'étude, tout élément nouveau me concernant et pouvant modifier mon
19 20	10	consentement me sera communiqué.
21 22 23	11	
24		
25 26	12	J'accepte que les données de mon dossier médical qui se rapportent à l'étude soient
27	13	accessibles aux responsables de l'étude et aux représentants des autorités de santé. A
28 29	14	l'exception de ces personnes, qui traiteront les informations dans le plus strict respect du
30 21	15	secret médical, mon anonymat sera préservé.
32 33	16	
34 35	17	l'ai pris connaissance que cette recherche a recu l'avis favorable du Comité de Protection
36	10	des Dersonnes et l'autorisation de l'ANSM le
37 38	10	
39 40	19	
40 41		
42 43	20	Le promoteur de la recherche (CHU de Grenoble) a souscrit une assurance de responsabilité
44	21	civile en cas de préjudice auprès de la société.
45 46	22	
47		
48 49	23	J'accepte que les données enregistrées à l'occasion de cette étude fassent l'objet d'un
50 51	24	traitement informatisé par le service de Physiologie Sommeil et Exercice du CHU de
52	25	Grenoble, responsable de l'analyse statistique. Je peux accéder, directement ou par
53 54	26	l'intermédiaire d'un médecin de mon choix, à l'ensemble de mes données médicales. Mon
55 56	27	droit d'accès, de rectification et d'opposition prévu par la loi "informatique et libertés"
57		
58 59		25

2	1	s'exerce à tout moment aunrès du médecin en	charge de la recherche	
4	1	s excrete a tout moment, aupres du medeem en		
5 6	2			
7 8	3	Mon acceptation de participer à l'étude ne dég	age pas les médecins et les organisateurs de	
9 10	4	l'étude de leur responsabilité. Je conserve tous	mes droits garantis par la loi.	
11 12 13	5			
14 15	6	J'ai reçu une copie du présent document et j'a	i été informé qu'une copie serait également	
16 17	7	conservée par l'investigateur et le promot	eur dans des conditions garantissant la	
18 19	8	confidentialité et j'y consens.		
20 21	9			
22	10	Je certifie avoir lu ce document ainsi que la notice d'information et accepte de participer,		
24 25	11	librement, à cette recherche, dans les conditions qui m'ont été précisées.		
26 27 28	12			
29 30	13	En cas d'événements indésirables ou de problèmes, ou si j'ai d'autres questions au cours de		
31 32	14	ma participation, je pourrai contacter le médecin en charge de la recherche au numéro de		
33 34	15	téléphone suivant :		
35 36 37	16			
38 39	17	Nom / Prénom du patient :	Nom du médecin :	
40 41	18			
42 43	19			
44 45	20	Date ://	Date ://	
40	21	Signature du patient :	Signature du médecin :	
48 49 50	22			
51 52	23			
53 54 55	24			
56 57 58	25		26	
59 60		For peer review only - http://bmjopen.b	mj.com/site/about/guidelines.xhtml	

59

1		
2		
3	1	
4		
5		
6		
/		
0 0		
10		
10		
12		
13		
14		
15		
16		
17		
18		
19 20		
20 21		
22		
23		
24		
25		
26		
27		
28		
29		
31		
32		
33		
34		
35		
36		
3/ 20		
30		
40		
41		
42		
43		
44		
45		
46 47		
4/ /8		
40 49		
50		
51		
52		
53		
54		
55		
56		
5/		

2 3 4	1	Supplementary material – Consent form (English version)			
5 6 7 8	2	Reduction of Sympathetic tone in OSA patients:			
9 10	3	Is CPAP more effective than APAP? – a randomized, parallel clinical trial protocol			
11 12	4	Short title : APAP-CPAP			
13 14	5	Study Sponsor: CHU de Grenoble – DRCI (Direction de la Recherche Clinique et Innovation) :			
15 16	6	CHILde Grenoble $CS$ 10217 38043 Grenoble Cedex 09 - Tel : 04 76 76 56 09 Eax : 04 76 76			
17 18	7	52 21			
19	·				
20 21	8	Principal investigator: Renaud Tamisier			
22 23	9	Members of Grenoble Alpes University Hospital participating in this study :			
24					
25 26	10	Pr Jean-Louis Pépin, Pr Renaud Tamisier, Pr Patrick Levy, Dr Marie Destors, Dr Erika Treptow,			
27 28	11	Dr. Holger Whorle: Physiologie Sommeil et Exercice - Pôle Locomotion Rééducation et			
28 29	12	Physiologie (Physiology, Sleep and Exercise – Centre for locomotion, Reeducation and			
30 31	13	Physiology); Dr Cecile Bosc: Centre Santé et Sommeil (Health and Sleep Center).			
32 33	14				
34 35	15	Drhas proposed that I participate in the study APAP-CPAP study. I have			
36	16	received detailed explanations about the objectives and procedures of the study, as well as			
37 38	17	its benefits, risks and constraints.			
39 40	18				
41 42	19	I have received an information sheet and I've had enough time to read it and to make the			
43 44	20	decision to participate, or not, in the study. I've had the opportunity to ask all my questions			
45	21	and I've received satisfactory answers. I understood that my participation in the study is			
46 47	22	voluntary and that I can, at any time, withdraw my consent, whatever my reasons, without			
48 49	23	incurring any responsibility and without any modification in the treatment received.			
50 51	24	I have been informed that this study will be conducted according to the French Code of			
52	25	Public Health, and have been assured that all study procedures will be made in accordance			
53 54	26	with the current medical recommendations.			
55 56	27	I have understood that I should not participate in any other biomedical research protocol			
57 58					
59		28			
60		for peer review only - http://binjopen.binj.com/site/about/guidelines.xhtilli			

1				
2 3	1	during the period of this study.		
4 5 2 During the study, I will be informed of any event concerning my health that				
6 7	my consent.			
8 9 4 I accept that the data in my medical file(s) related to the study will be a				
10	5	study's collaborators and to representatives of the health authorities. With the exception $\sigma$		
12	6	these people, who will deal with my data in respect of professional secrecy, my anonymity		
13 14	7	will be preserved.		
15 16	8	I have been informed that this research has been approved by the Regional Biomedica		
17	9	Ethics committee (Comité de protection de Personnes) and authorized by the French		
10 19	10	National Agency for the Safety of Medicines and Health Products.		
20 21	11	The sponsor of the study (Grenoble Alpes University Hospital) has contracted an additiona		
22 23	12	insurance of civil responsibility in case of harms.		
24 25	13	I accept that the data concerning me acquired during this study will be registered by the		
26 27	14	Department of Physiology, Sleep and Exercise of Grenoble Alpes University Hospital, which is		
28	15	responsible for the statistical analysis. I have the right to access, directly or through a		
29 30	16	physician of my choice, the set of information and medical data concerning me. At any time		
31 32	will have the right of access and correction of computerized data according to the law or			
33 34	18	"informatique et libertés" through the physician responsible for the research.		
35	19 My acceptance to participate in the study does not discharge the organizers a			
37	20	investigators of the study from their responsibilities. I retain all my rights guaranteed by law.		
38 39	21	I have received a copy of the current consent sheet and I was informed that one copy will be		
40 41	22	retained by the investigator and another by the sponsor under conditions guaranteeing		
42 43	23	confidentiality.		
44	24	I certify that I have read this document as well as the patient information sheet and I freely		
46	<ul><li>45</li><li>46 25 accept to participate in the study according to the conditions specified.</li></ul>			
47 48	26	In case of any undesirable events or problems, or if I have any other questions during my		
49 50	49 50 27 participation of the study, I may contact the physician responsible for the research			
51 52	28	the telephone number +33 (0)4 76765516.		
53 54	29			
55 56	30	Surname / First Name of participant : Surname of investigating physician in :		
57				
58 59		29		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml		

1			
2 3	1		
4			
5	2		
7	3	Date: / /	Date: / /
8	5		
9 10	4	Participant's signature :	Physician's signature :
11	5		
12 13			
14	6		
15	7		
16 17			
18	8		
19 20			
20	9		
22			
23 24			
25			
26 27			
27 28			
29			
30 31			
32			
33			
35			
36			
37 38			
39			
40 41			
42			
43			
44 45			
46			
47 48			
49			
50 51			
51 52			
53			
54 55			
56			
57 59			
58 59			
60		For peer review only - http://bmjopen.k	omj.com/site/about/guidelines.xhtml



Figure 1. Settings, acquisition, recording and reporting of muscle sympathetic nerve activity (MSNA). Measurement of MSNA is obtained by placement of an un-insulated tungsten register electrode in the peroneal nerve in the popliteal fossae or close to the fibula head. The objective is to reach post ganglionic efferent sympathetic neurons. Potential voltage signal is recorded between the nerve electrode and a reference electrode placed on the external side of the knee. The acquired electrical signal is then amplified, band-filtered (700 to 2000 Hz), rectified and integrated. Sympathetic burst, which correspond to nerve firing, are detected and scored using an automatic software in order to minimize subjective interpretation of the signal MSNA results may be expressed in number of bursts per min or per 100 heart beats, Burst/min and bursts/100 hb respectively or using the sum of areas under the curve of all burst in arbitrary integration units per minute or per 100 heart beats, AUI/min and AUI/100 hb respectively.

254x142mm (300 x 300 DPI)



# **BMJ Open**

## Reduction in sympathetic tone in Obstructive sleep apnea patients: is fixed CPAP more effective than APAP? – a randomized, parallel trial protocol

Journal:	BMJ Open
Manuscript ID	bmjopen-2018-024253.R1
Article Type:	Protocol
Date Submitted by the Author:	09-Oct-2018
Complete List of Authors:	Treptow, Erika; 1. Université Grenoble Alpes, Pepin, Jean; Hôpital Universitaire de Grenoble, Bailly , Sebastien; Centre Hospitalier Universitaire Grenoble Alpes Hopital Michallon Levy, P; Hypoxia Pathophysiology (HP2) Laboratory Joseph Fourier University Bosc , Cecile ; Centre Santé et Sommeil Destors, Marie; Centre Hospitalier Universitaire Grenoble Alpes Hopital Michallon Woehrle, Holger; Lung Center Ulm Tamisier, Renaud; Univ. Grenoble Alpes, HP2; Inserm, U1042; Grenoble Alps University Hospital, EFCR Laboratory
<b>Primary Subject Heading</b> :	Cardiovascular medicine
Secondary Subject Heading:	Diagnostics, Respiratory medicine
Keywords:	obstructive sleep apnea, Hypertension < CARDIOLOGY, continous positive airway pressure, SLEEP MEDICINE, sympathetic activity

SCHOLARONE<sup>™</sup> Manuscripts

1 2		
3 4	1	Reduction in sympathetic tone in Obstructive sleep apnea patients:
5 6 7	2	is fixed CPAP more effective than APAP? – a randomized, parallel
8 9	3	trial protocol
10 11	4	Erika Treptow <sup>1</sup> , Jean-Louis Pépin <sup>1</sup> , Sebastien Bailly <sup>1</sup> , Patrick Levy <sup>1</sup> , Cecile Bosc <sup>2</sup> , Marie
12 13	5	Destors <sup>1</sup> ,Holger Woehrle <sup>3</sup> ,Renaud Tamisier <sup>1</sup>
14 15	6	
16 17	7	1. University Grenoble Alpes, HP2 laboratory; Inserm U1042, Grenoble, France and
18 10	8	Grenoble Alpes University Hospital, EFCR Laboratory, Thorax and Vessels Division,
20	9	Grenoble, France.
21 22	10	2. Health and Sleep Center, Grenoble, France.
23 24 25	11	3. Sleep and Ventilation Center Blaubeuren/ Ulm Lung Center, Ulm, Germany
26	12	Sponsor: Grenoble Alpes University Hospital
27 28 29	13	CS 10217, 38043 Grenoble Cedex 09 France
30 31	14	Corresponding authors: Renaud Tamisier and Erika Treptow
32	15	EFCR Laboratory, Grenoble Alpes University Hospital
33 34 25	16	CS 10217 Grenoble 38043 Cedex 09 France
35 36 37	17	e-mail: <u>rtamisier@chu-grenoble.fr</u> ; <u>erikatpw@hotmail.com</u>
38 39 40	18	Phone: +33 (0)476765516
41 42	19	Sources of support: ET is supported by Coordenação de Aperfeiçoamento de Pessoal de Nível
43	20	Superior (CAPES) – Brazil. This work was supported by unrestricted grants from ResMed,
44 45	21	foundation Agir pour les maladies chroniques and by the French National Research Agency in
46 47 48	22	the framework of the "Investissements d'avenir" program (ANR-15-IDEX-02).
49 50	23	Word count: 3104
51 52 53	24	Number of figures and tables: 2 figure and 2 tables
54 57	25	
55 56 57 58	26	
59 60		1 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
1		
----------------	----	---
2	1	
3 4	1	
5 6	2	Abbreviations:
7 8	3	ABPM: ambulatory BP monitoring
9 10	4	AHI: apnea and hypopnea index
11 12	5	APAP: auto-adjusting continuous pressure
13	6	BP: blood pressure
15	7	CPAP: continuous positive airway pressure
17	8	DBP: diastolic blood pressure
18 19	9	ECG: electrocardiography
20 21	10	EEG: electroencephalography
22 23	11	EMG: electromyography
24 25	12	EOG: electrooculography
26 27	13	HRV: heart rate variability
28 29	14	ITT: intention-to-treat analysis
30 31	15	MBP: mean blood pressure
32 33	16	MSNA: muscle sympathetic nerve activity
34 35	17	OSA: obstructive sleep apnea
36 37	18	PPT: per protocol analysis
38 39	19	SBP: systolic blood pressure
40 41	20	
42 43	21	
44 45	22	
46 47	23	
48 49	24	
50 51	25	
52	26	
55 54	27	
55 56 57	28	
58		
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 3 of 41

#### **BMJ** Open

## 1 Abstract (Word count: 299)

Introduction: Obstructive sleep apnea (OSA) is a prevalent disease associated with cardiovascular events. Hypertension is one of the major intermediary mechanisms leading to long-term cardiovascular adverse events. Intermittent hypoxia and hypercapnia associated with nocturnal respiratory events stimulate chemo-reflexes, resulting in sympathetic overactivity and blood pressure (BP) elevation. Continuous positive airway pressure (CPAP) is the primary treatment for OSA and induces a small but significant reduction in BP. The use of auto-adjusting continuous pressure (APAP) has increased in the last years and studies showed different ranges of BP reduction when comparing both modalities. However, the pathophysiological mechanisms implicated are not fully elucidated. Variations in pressure through the night inherent to APAP may induce persistent respiratory efforts and sleep fragmentation that might impair sympatho-vagal balance during sleep and result in smaller decreases in BP. Therefore, this double blind randomized controlled trial aims to compare muscle sympathetic nerve activity (MSNA) assessed by microneurography (reference method for measuring sympathetic activity) after one month of APAP versus fixed CPAP in treatment-naive OSA patients.

Methods and analysis: adult subjects with newly diagnosed OSA (apnea hypopnea index > 20/h) will be randomized for treatment with APAP or fixed CPAP. Measurements of sympathetic activity by MSNA, heart rate variability and catecholamines will be obtained at baseline and after 30 days. The primary composite outcome will be the change in sympathetic tone measured by MSNA in bursts/min and bursts/100 heart beats. Sample size calculation was performed with bilateral assumption. We will use the t-Student test to compare changes of sympathetic tone between groups. 

4524Ethics and dissemination: The protocol was approved by The French Regional Ethics4625Committee and registered on ClinicalTrials.gov (NCT03428516). The study started in March48262018 with primary completion expected to March 2019. Dissemination plans of the results5027include presentations at conferences and publication in peer-reviewed journals.

28 Trial registration number: NCT03428516

1	Kowwords: obstructive sleep appeal bypertension, continuous positive airway pressure, sleep
1	Reywords. Obstructive sleep apried, hypertension, continuous positive an way pressure, sleep
2	medicine, sympathetic activity.
3	
4	Strengths and limitations of the study:
5	• The analysis of vascular and cardiac sympathetic activity will be evaluated by
6	complementary methods: microneurography of the peroneal nerve (the gold
7	standard method), heart rate variability (HRV) and urinary catecholamines.
8	• The use of 24h ambulatory blood pressure (BP) monitoring is more sensitive when
9	assessing therapeutic interventions than office BP and provides prognostic guidance.
10	A statistician not involved in the data collection will randomly allocate subjects to one
11	of the two positive airway pressure (PAP) modalities. All other investigators, patients
12	and assessment technicians will be blinded to the patient's group.
13	• The same make and model of CPAP device will be used both in Fixed and APAP
14	modes
15	The duration of exposure to treatment of one month is ample but might under-
16	represent the chronic effects of PAP therapies on sympathetic activity
10	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
	4
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

### BMJ Open

## Introduction

Obstructive sleep apnea (OSA) is associated with increased cardiovascular morbidity and mortality (1-6). Hypertension is the main intermediary mechanism implicated in cardiovascular risk (7-9). There is a dose-response relationship between indices of OSA severity and hypertension (10, 11). Accordingly, one of the most common objectives when treating OSA is blood pressure (BP) reduction in order to prevent or reduce long-term cardiovascular adverse events.

OSA is characterized by partial (hypopnea) or complete (apnea) upper airway collapses during sleep (12). Sympathetic activation is the main intermediary mechanism for BP elevation in OSA patients (11, 13). The repetitive occurrence of respiratory events leading to intermittent hypoxia and hypercapnia results in stimulation of central and peripheral chemoreflexes enhancing sympathetic activity and, subsequently increasing vascular tone and promoting blood pressure elevation (14). Chronic sympathetic activation induces vascular remodeling and, frequently, uncontrolled or resistant hypertension(15). In OSA patients, nighttime sympathetic over-activation is associated with the non-dipping pattern of BP and the high sympathetic tone persists during wakefulness (16). In the early course of the disease, even non-hypertensive subjects exhibit increased BP and muscle sympathetic nerve activity in response to chronic intermittent hypoxia (13, 17). Muscle sympathetic nerve activity (MSNA) is one of the reference methods for measuring sympathetic activity and understanding the pathophysiology of neurogenic hypertension (18). Moreover, MSNA changes across time or after intervention are corresponding with arterial blood pressure changes in prehypertension (19).

In different models of hypertension only intermittent hypoxia, which is the main stimuli in OSA, causes neurogenesis modulation in hippocampus (20). In human, intermittent hypoxic exposure induces after 2 and 4 weeks an increase in daytime MSNA (13, 17). This increase in sympathetic tone was suggested in the early 90ies as a mechanism of hypertension in OSA (16, 21). Therefore, MSNA measurement is of particular interest in showing the effect of OSA treatment as a surrogate marker of cardiovascular outcomes. Although several studies have demonstrated the beneficial effects of OSA treatment by continuous positive airway pressure (CPAP) in sympathetic activation (14, 22-24), this 

measurement has never been evaluated in patients under Auto-adjusting continuous pressure (APAP). MSNA consists of a technique of microneurography minimally invasive that measures the sympathetic nerve activity of the peroneal nerve.

CPAP remains the gold standard therapeutic option for the treatment of moderate and severe OSA. Several systematic reviews and meta-analyses (25-31) have demonstrated limited but significant improvements in BP (a reduction of about 2 mmHg in 24-h mean BP). Better results are achieved in specific phenotypes with more severe OSA, higher BP at baseline and adherent to PAP therapies (use of CPAP  $\geq$  4 hours/night)(26, 32-34).

APAP changes the pressure delivered throughout the night depending on events detected, with the goal of applying the minimal effective pressure (35-38) thus reducing side effects and improving adherence. The average overnight applied pressure is significantly lower with APAP for the same range of improvement in the apnea-hypopnea index (AHI) (39). However, the continuous variations in pressure associated with the functioning of APAP devices potentially induce micro-arousals, and change sleep macrostructure in some patients (38, 40, 41). This might limit the decrease in sympathetic activity during the night when treating OSA and consequently result in a smaller reduction of BP. 

Studies have demonstrated controversial results on the impact of the two pressure modalities (fixed versus auto-adjusting) on blood pressure reduction (table 1). Although some authors reported superiority with fixed pressure (42, 43) other clinical trials reported no significant difference between APAP and CPAP (44-46). A recent study that evaluated 208 patients with a longer than usual follow up of 2 years demonstrated comparable reductions in sleepiness and blood pressure with similar OSA-related costs for both treatments (44). Karasulu et al(47) and Patruno et al(48) have demonstrated lower reduction in cardiac sympathetic activity using heart rate variability (HRV) in OSA patients and obese OSA patients during APAP treatment compared with fixed CPAP. However, neither study was randomized and Patruno evaluated only a specific population of obese patients with severe OSA, which limits the generalizability of the results. In a small study of adult males, without antihypertensive treatment, Marrone et al(41), evaluated BP changes after treatment with APAP versus CPAP. As a secondary outcome, they reported sympathetic activity by measurement of catecholamines. Norepinephrine decreased significantly after treatment in 

2				
2 3	1	the APAP group but not in the CPAP group and normetanephrine decreased significantly in		
4 5	2	both groups. Overall, there is a lack of well-designed studies evaluating the mechanisms		
6 7	3	underlying specific BP responses under APAP versus fixed CPAP. In this context, the aim of		
8	4	the present study is to compare vascular sympathetic tone after one month of treatment		
9 10	5	with fixed versus auto-adjusting pressure by microneurography in newly diagnosed OSA		
11 12	6	patients.		
13 14	7	Methods and analysis		
15				
16 17	8	<u>Study design</u>		
18 19	9	This study is a prospective, single-site, randomized, double-blind, parallel, one		
20 21	10	month-controlled trial.		
22				
23 24	11	<u>Objectives</u>		
25 26	12	Primary research objective		
20 27				
28 29	13	The main objective is to compare change in vascular sympathetic tone measured by		
30	14	Muscle Sympathetic Nerve Activity (MSNA) microneurography after one month of APAP		
31 32	15	versus after one month of fixed CPAP in treatment-naive moderate to severe OSA patients.		
33 34	16	The primary composite outcome will be the change in sympathetic tone measured by		
35 36	17	MSNA in bursts/min and bursts/100heart beats between baseline and after one month of		
37 38	18	treatment.		
39				
40 41	19	Secondary research objectives		
42	20	The secondary objectives will be to compare the following variables before and after		
45 44	21	treatment:		
45 46				
47	22	- Ambulatory BP monitoring (24h ABPM): mean blood pressure (MBP),systolic blood		
48 49	23	pressure(SBP) and diastolic blood pressure DBP, during 24h periods as well as daytime and		
50 51	24	night-time measurements.		
52 53	25	- Urinary catecholamines (24h collection): epinephrine, norepinephrine, and dopamine.		
54 55	26	- Heart Rate Variability as an indicator of cardiac sympathovagal balance.		
56 57	-	, , , , , , , , , , , , , , , , , , , ,		
58		7		
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml		

# 1 <u>Population</u>

Consecutive adult outpatients attending a tertiary hospital sleep center (*Grenoble Alpes University Hospital* – France), with an established diagnosis of obstructive sleep apnea by full-night polysomnography (apnea-hypopnea index > 20/hour), daytime sleepiness (Epworth Sleepiness Scale > 10) (49) and willing to receive positive airway pressure treatment, will be invited to participate in the study. The inclusion and exclusion criteria are presented in table 2. Written informed consent will be obtained from all participants by a sleep physician study investigator (supplementary file).

- Materials

## <u>Muscle Sympathetic Nerve Activity (MSNA)</u>

We will obtain MSNA from nerve recordings using standard tungsten microelectrodes inserted into the peroneal nerve into the popliteal area, after localization by electric surface stimulation (Figure 1). Signals will be filtered (700-2000 Hz), amplified (x 70,000) and full-wave rectified. The rectified signal will be integrated (0.1 second moving window) for display and for recording (Nerve Traffic Analyzer, Model 662c-3, University of Iowa, Bioengineering Dept., Iowa City, IA). Electrode position in muscle fascicles will be confirmed by pulse synchronous bursts of activity occurring 1.2-1.4 s after the ECG QRS complex, reproducible activation during the second phase of the Valsalva maneuver, elicitation of afferent nerve activity by mild muscle stretching and the absence of response to startle. Doppler popliteal vascular flows (DWL500EZ) will be measured during time periods concomitant from measurement of MSNA, HR (3-lead ECG) and arterial blood pressure. Beat-by-beat arterial BP for vascular doppler leg resistance calculations will be measured using the CNAP® system the same time period. All these signals will be digitalized and recorded for off-line analysis on Powerlab system. These measurements will be performed before and after PAP therapy on morning sessions, fasten since 12 AM from foods and any beverage except water, during room air breathing. We will average nerve activity, heart rate and arterial BP over 5-minute windows of data collection at baseline and post-PAP therapy. Sympathetic bursts will be identified using a specific algorithm described by Hamner and colleagues (50) using Matlab software (The Mathworks Inc., Natick, MA USA). For purposes of quantification MSNA will be

#### **BMJ** Open

reported in at least five minutes periods and expressed as burst frequency (bursts/min and bursts/100 heart beats).

<u>Blood flow</u>

Popliteal blood velocity will be recorded using a 4-MHz Doppler probe (Multidop T2, DWL) at the popliteal fossa of the contralateral leg to the sympathetic nerve recording.

Several parameters will be extracted from the above measurements: sympathetic vascular tone, blood pressure and blood flow. Furthermore, we shall calculate vascular resistance and vascular sympathetic tone and blood pressure gains, as previously described (14, 51).

<u>Blood Pressure</u>

Ambulatory blood pressure monitoring (ABPM) will be measured in the dominant arm over 24 hours at 15 min intervals during daytime and every 30 minutes nighttime (ABP monitor 90207, Spacelabs Healthcare, Issaquah WA). Blood pressure acquisition began at a morning session and ended 24 hours later. The following ABPM parameters will be studied: mean SBP, mean DBP and mean HR over 24 hours, the same mean values during the daytime (7.00 am to 10.00 pm) and at night-time (10.00 pm to 7.00 am). The normal night-time physiological dipping BP is expected to be > 10%. The summary values in the ABPM report for each patient will be used in the data analysis. This is an average by subject and by recording session (at baseline and 1 month). Data relating to the average daytime and night-time systolic BP (SBP), diastolic BP (DBP), and mean BP (MBP) will be recorded. SBP values of > 260 mmHg or < 70 mmHg and DBP > 150 mmHg or < 40 mmHg will be automatically eliminated. Daytime hypertension is defined as daytime SBP > 135 mmHg and/or DBP > 85 mmHg, and night-time hypertension as SBP > 120 mmHg and/or DBP > 70 mmHg (52). 

Clinical BPs (SBP and DBP) will be measured by mercury sphygmomanometer on three occasions in line with the European Society of Hypertension–European Society of Cardiology and American College of Cardiology/ American Heart Association guidelines(9, 53). Mean arterial BP (MABP) will be calculated as DBP + 1/3(SBP-DBP).

Each recording will be validated only if the following quality criteria are met: cuff size adapted to the diameter of the arm, calibration of the device, full 24 hours' duration of recording comprising at least 48 valid measures and no more than two missing time slots.

#### Catecholamine measurements

24h urine samples will be collected, acidified with acetic acid and stored at -20°C until analysis. Catecholamines (epinephrine, norepinephrine, and dopamine) will be measured in one millilitre of urine by high-performance liquid chromatography with electrochemical detection (Coularray Detector, ESA Dionex, Chelmsford, USA).

#### <u>Polysomnography</u>

Full night polysomnography will be performed at our sleep laboratory. The following physiological variables will be monitored: electroencephalography (EEG), electrooculography (EOG), electromyography (EMG), electrocardiography (ECG), oral and nasal airflows, chest and abdominal respiratory effort through inductance plethysmography, snoring, body position, oxyhemoglobin saturation by pulse oximetry and heart rate. Continuous recordings will be taken with electrode positions C3/A2-C4/A1-Cz/01 of the international 10-20 Electrode Placement System, along with eye movements, chin electromyogram and ECG with a modified V2 lead. Airflow will be measured with nasal pressure prongs together with the sum of oral and nasal thermistor signals. Respiratory effort will be monitored using abdominal and thoracic bands. Oxygen saturation will be measured using a pulse oximeter. Respiratory events will be classified according to the American Academy of Sleep Medicine's guidelines (54). An apnea is defined as the complete cessation of airflow for at least 10 seconds and hypopnea as a reduction of at least 30% in the nasal pressure signal associated with either oxygen desaturation of  $\geq$ 3% or an EEG arousal from sleep, both lasting for at least 10 seconds. Apneas will be classified as obstructive, central or mixed according to the presence or absence of respiratory effort. The classification of hypopneas as obstructive or central will be based on the thoraco-abdominal band signal and the shape of the nasal respiratory pressure curve (flow limited aspect or not). The AHI is defined as the number of apneas and hypopneas per hour of sleep. Sleep will be scored manually according to AASM criteria (54).

#### BMJ Open

### 

### <u>Procedures</u>

At the baseline visit, MSNA, ABPM, calf blood flow, HRV and catecholamines will be measured. Then, during a one week titration phase optimal CPAP pressure will be obtained over eight nights at home using an auto CPAP device (RESMED<sup>TM</sup>) to obtain a fixed CPAP pressure value. The optimal pressure (95th percentile) will be determined by one expert researcher, based on visual evaluation of the raw data recordings from nights with no significant leaks. The pressure determined during the titration nights will be used as the therapeutic pressure in the fixed CPAP mode, whereas in APAP the pressure level will be adjusted between a minimal pressure of 6 cmH<sub>2</sub>O and a maximum of 16 cmH<sub>2</sub>O. After the titration phase, participants with a minimum usage of 4 hours per night will be randomized to treatment with either APAP or fixed CPAP. During treatment, the healthcare provider of the device (Agiradom) will be responsible for solving potential problems with usage (e.g. mask leaks, side effects). The healthcare provider employees are trained in research good clinical practice, and how to maintain the blindness of allocation to patients and researchers during randomized trials. Finally, following one month of treatment, MSNA, ABPM, calf blood flow, HRV and catecholamines will be measured for comparison with baseline. Figure 2 shows the study schema. 

34 18 <u>Statistical considerations</u>

### 19 Sample size

We powered the study based on the MSNA outcome. To date no previous study has compared these two PAP modalities using MSNA as primary outcome. Since there are no reliable MSNA data available, we hypothesized the impact of CPAP to be 8±5 bursts/min in one arm and 5±5 bursts/min in the other arm with no *a priori* assumption . Assuming an alpha error of 5%, a statistical power of 80%, in bilateral situation, 34 patients per arm will need to be enrolled in the study. In the sample size, we anticipate that 10 % will not meet the criteria of compliance to pressure support after 1 week, and 10% more will drop out before termination of the study.

Because it is a pilot study, we will perform a group sequential design, firstly an interim analysis will be performed on data from the first 24 patients (12 per arm) with a

nominal p value of 0.0081 required to demonstrate a significant difference between groups. If at the interim analysis, the observed p value for the primary outcome is greater than the nominal p value inclusions will continue until the final sample of 68 patients is reached. Conversely, if significance is observed, the patient inclusion would stop and no further inclusions will be needed. This interim analysis will be performed by a blinded statistical which have no regard on the randomization list neither contacts with the investigator nor involvement in the study.

#### Randomization

After titration of fixed CPAP (lasting 8 nights), participants with a minimum usage of 4 hours per night will be randomized to either fixed CPAP or APAP treatment. Randomization will be conducted by a statistician independent of the study using a computer-generated random numbers list (6 patients per block). Randomization list was provided by the clinical research department of Grenoble Alpes university hospital and the randomization list is held and followed by two independent persons from the study. These persons provide allocation directly to the healthcare provider maintaining blindness of the patient and the 4.8 investigators.

#### Statistical methodology and analyses

The analysis will be done following the Intention to treat method. Continuous variables will be expressed as median (25th/75th percentiles) or mean (SD), while categorical variables will be reported as absolute numbers and percentages for both groups. Baseline comparisons between groups will be made using a Student test or Mann-Whitney test, depending on validation of normal distribution. For discrete variables, a Chi-square test will be used. Normality will be assessed using the Shapiro-Wilk test. If significant differences are observed between arms, a multivariable regression will be performed. In case of missing data, an imputation strategy will be applied according to the percentage of missing values. If less than 5% of missing value are observed, simple imputation will be performed, based on the median for quantitative variables or on the most frequent values for qualitative variables. If the proportion of missing values is between 5 and 20%, multiple imputations will be performed by using MCM chains for qualitative variables or full conditional specification for quantitative variables. Variables with more than 20% of missing values will not be taken

#### **BMJ** Open

into account. The main outcome, difference between one-month and baseline values will be analyzed by using a Student t-test. In case of multivariable analysis, a linear mixed model will be performed by including a random effect for patient.

Data management and statistical analyses will be performed using SAS<sup>®</sup> (version 9.4, SAS Institute, Cary, NC, USA).

## Ethics

The current study will be conducted in accordance with the Declaration of Helsinki and the recommendations for Good Clinical Practice. The protocol was approved by The French Regional Ethics Committee (*Comite de Protection des Personnes Sud Est* V N° IRB: 0006705 on 19 February 2018). Written informed consent (supplemental file) will be signed by all study participants before enrollment in the study. Patients have the right to withdraw from the study without incurring any prejudice at any time. The protocol is registered on the ClinicalTrials.gov website (NCT03428516). The study started in March 2018 with primary completion expected in March 2019. 

### Patient and Public Involvement

Patients, collaborators and sponsors were not directly involved in the design, recruitment and conduction of the study. Dissemination plans of the results include presentations at conferences and publication in peer-reviewed journals. Updates of the randomized trial will be available at ClinicalTrials.com. All patients will be informed that the dissemination of results will be accessible on request.

#### Sponsor and funding

The sponsor of the study is Grenoble Alpes University Hospital, France. The principal investigator is Renaud Tamisier. Erika Treptow is supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) – Brazil. ResMed, "Agir pour les maladies chroniques" and the French National Research Agency in the framework of the "Investissements d'avenir" program (ANR-15-IDEX-02) will provide unrestricted funding. The collaborators and sponsors were not involved in the design of the study and will not influence the execution, analysis and publication of results.

2

3

4

5

6

7

8

9

10

11

12

1

2	
3	
4	
5	
6	
7	
, 0	
ð	
9	
10	
11	
12	
13	
11	
14	
15	
16	
17	
18	
19	
20	
20	
∠ I 22	
22	
23	
24	
25	
26	
27	
27	
28	
29	
30	
31	
32	
22	
JJ ⊃⊿	
34	
35	
36	
37	
38	
39	
10	
40	
41	
42	
43	
44	
45	
46	
-10 /17	
4/	
48	
49	
50	
51	
52	
52	
22	
54	
55	
56	
57	
58	
50	
22	
60	

## **Discussion**

CPAP remains the first-line therapy for OSA patients. In order to determine the optimal pressure that will maintain airway patency during sleep, a titration made during full night polysomnography is required. However, this is costly, demands technical expertise and may result in a delay in the initiation of treatment. Furthermore, night-time AHI can be variable, depending on position, sleep architecture, overnight rostral fluid shifts and alcohol intake, which may influence the determination of the optimal effective pressure if performed during only one night(55, 56). Therefore, over the last few years there has been an exponential increase of the use of APAP for automatic titration prior to long-term treatment at home. This simplified procedure is associated with comparable outcomes (57) and a significant cost reduction (58).

13 Currently, in many countries especially in Europe, APAP is by far the most commonly used device for OSA treatment and gives a slight increase in PAP adherence (59). However, 14 15 the increase in APAP use is accompanied by unresolved scientific questions: is APAP as 16 effective as fixed CPAP in reducing cardiovascular risk? Is it safe to use APAP in patients with comorbidities? Do APAP and CPAP have the same efficacy in normalizing sleep in patients 17 18 with OSA? The proposed study will focus on the cardiovascular response to these different 19 PAP modalities. To achieve this, we shall use complementary reference tools to evaluate 20 sympathetic activity in patients using fixed CPAP or APAP. Vascular and cardiac sympathetic 21 activity will be explored in addition to circulating catecholamine levels.

22 Since its first description in 1967 (60) vascular sympathetic activity measured by 23 microneurography has provided insights into our understanding of the pathophysiology of 24 hypertension, cardiac failure and sleep apnea (16, 18, 61). This method allows the recording 25 of impulses in peripheral nerves and is the gold standard for measurement of vascular 26 sympathetic activity. When applied by experienced professionals, MSNA is reproducible and 27 allows evaluation between subjects before and after an intervention, with minor risks and side effects (51, 62). It has been demonstrated that intermittent hypoxia is a major 28 contributor to inducing sympathetic activation in healthy humans and patients with OSA (13, 29 30 17, 63) and that treatment with CPAP lowers MSNA (23). One of the strengths of the present

1								
2 3	1	study is that, in addition to MSNA, we will measure heart rate variability and urinary						
4 5	2	catecholamines to assess cardiac and whole body sympathetic activity respectively.						
6 7	3	Moreover, we will provide a better understanding of BP responses under the two PAP						
8	4	therapies and possibly identify the type of patients who would benefit the most from A						
9 10	5	The sympathetic APAP-CPAP protocol is key randomized controlled trial that will assess, for						
11 12	6	the first time, different PAP modalities that might differ in terms of the decrease in						
13	7	sympathetic activity they induce in patients with OSA. The results of the APAP-CPAP study						
14	8	should provide further clarification as to the cardiovascular benefits of an effective						
16 17	9	treatment for patients with OSA. In addition, the findings might have important implications						
18 19	10	for individualized therapeutic strategies by identifying the best phenotypes to be treated by						
20	11	a given PAP therapy.						
21 22	12							
23 24	13	Author contributions						
25 26	14	ET participated in the design of the study, wrote the article based on the study protocol, will						
20	15	include patients, collect and analyze data into the protocol.						
28 29	16	JLP and PL designed the study, wrote the study protocol, critically revised the manuscript						
30 31	17	and will include patients into the protocol.						
32	18	SB participated in the design of the protocol, established the statistical analysis plan, and						
33 34	19	calculated the sample size.						
35 36	20	CB revised the manuscript and will include patients into the protocol.						
37 38	21	MD revised the manuscript and will include patients into the protocol.						
39	22	HW participated in the design of the study and critically revised the manuscript.						
40 41	23	RT designed the study, wrote the study protocol and article, critically revised the manuscript						
42 43	24	and will include patients, and collect and analyze data.						
44 45	25	The submitted manuscript has been approved by all authors.						
46	26							
47 48	27	Acknowledgements						
49 50	28	The authors would like to thank Marie Peeters for trial management and Alison Foote						
51	29	(Grenoble Alpes University Hospital, Research division) for language revision.						
52	30							
54 55	31	Funding						
56 57	51							
58		16						
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml						

1		
2 3	1	ET is supported by Coordenação de Aperfeicoamento de Pessoal de Nível Superior
4	r	(CAPES) - Provid This work was supported by uprostricted grant from PosMed, by the
5 6	2	(CAPES) - Brazil. This work was supported by unrestricted grant norm resided, by the
7	3	foundation Agir pour les maladies chroniques and by the French National Research Agency in
8	4	the framework of the "Investissements d'avenir" program (ANR-15-IDEX-02).
9 10	_	
11	5	<u>Competing interests</u>
12	6	RTamisier reports travel grants from Agiradom (a Home Healthcare provider) and
14	7	research grants from Permed
15 16	/	research grants nom kesmed.
17	8	
18 19	9	Ethics approval
20	10	
21	10	The protocol was approved by the French Regional Ethics Committee (Comite de
22	11	Protection des Personnes SudEst V) on 19 February 2018 and is registered on
24	12	ClinicalTrials.gov (NCT03428516).
25 26	13	
27	14	Patient consent
28 29	1	Written informed concent will be signed by all study participants before enrollment.
30	15	written morned consent will be signed by all study participants before enrollment
31 32	16	in the study (see supplement materials).
33	17	
34 35	18	
36	19	
37 38	20	
39		
40 41	21	
42	22	
43	23	
44	24	
46		
47 48	25	
49		
50 51	26	
52	72	
53 54	27	
55	28	
56 57		
58		17
59 60		For peer review only - http://bmiopen.bmi.com/site/about/quidelines.xhtml
00		

# Tables

37 <sub>4</sub>

<sup>38</sup> 5 

# Table 1. Literature on the impact of CPAP versus APAP on BP

Author	Year	Sample	Study design	Duration	Intervention	Findings
(ref.)		Size				
Bloch KE	2017	208	Randomized,	2 years	APAP (5-15 cmH <sub>2</sub> O) vs CPAP (90 <sup>th</sup>	Reduction in MBP, SBP and DBP by 3-4 mmHg (ITT) and 4-6 mmHg (PPT),
(44)			parallel		percentile during titration)	similar in APAP x CPAP *
Pépin JL	2016	322	Randomized,	4 months	APAP (minimal interval of 5 cmH <sub>2</sub> O)	CPAP was more effective in reducing 24h DBP than APAP * †
(43)			parallel		vsCPAP (95 <sup>th</sup> percentile during	
					titration)	
Marrone O	2011	17	Randomized,	2 months	APAP (5-18 cmH <sub>2</sub> O) vs CPAP (fixed	Treatment reduced SBP during sleep and DBP during both sleep and
(45)			parallel		pressure determined during	wakefulness. Similar reductions in BP were demonstrated in both groups $\ensuremath{^*}$
					titration)	
Patruno V	2007	31	Randomized,	3 months	APAP (4-15 cmH $_2$ O) vs CPAP (fixed	Significant reduction in SBP (from 144 $\pm$ 10 to 132 $\pm$ 8 mm Hg; p < 0.001)
(42)			parallel		pressure determined during	and DBP (from 88 $\pm$ 4 to 79 $\pm$ 6 mmHg; p < 0.001) in the CPAP group but not
					titration)	in the APAP group (SBP, 142 $\pm$ 12 to 136 $\pm$ 6 mm Hg;DBP, 87.5 $\pm$ 4 to 86 $\pm$ 4
						mm Hg) †
West SD	2006	98	Randomized,	6 months	APAPvs APAP for 1 week and then	No difference between groups in MBP *
(46)			parallel		CPAP (95 <sup>th</sup> percentile during	
					titration)or CPAP (determined by	
					an algorithm)	

CPAP, continuous positive pressure; APAP, auto-adjusting continuous positive pressure; BP, blood pressure; MBP, mean blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; ITT, intention-to-treat analysis; PPT, per protocol analysis.

\*Ambulatory Blood Pressure Monitoring (24h) + Office blood pressure measurements.

Table 2. Inclusion and exclusion criteria	
Inclusion criteria	Exclusion criteria
Patients aged 18 to 80 years	Pregnancy
OSA (AHI ≥ 20 events/ h)	Person deprived of liberty or subject to a
	legal protection measure.
Daytime sleepiness	Patient with heart failure
Naive of any pressure treatment for OSA	Patient with central sleep apnea index above
	20% of AHI
Able to provide written informed consent	Patient with unstable comorbidities that
	could influence the results
Not a vulnerable person or legally protected	
adult	
OSA, obstructive sleep apnea; AHI, apnea hyp	popnea index

## 1 Figure legend

Figure 1. Settings, acquisition, recording and reporting of muscle sympathetic nerve activity (MSNA). Measurement of MSNA is obtained by placement of an un-insulated tungsten register electrode in the peroneal nerve in the popliteal fossae or close to the fibula head. The objective is to reach post ganglionic efferent sympathetic neurons. Potential voltage signal is recorded between the nerve electrode and a reference electrode placed on the external side of the knee. The acquired electrical signal is then amplified, band-filtered (700 to 2000 Hz), rectified and integrated. Sympathetic burst, which correspond to nerve firing, are detected and scored using an automatic software in order to minimize subjective interpretation of the signal MSNA results may be expressed in number of bursts per min or per 100 heart beats, Burst/min and bursts/100 heart beats respectively or using the sum of areas under the curve of all burst in arbitrary integration units per minute or per 100 heart beats, AUI/min and AUI/100 heart beats respectively.

Figure 2. Study protocol

MSNA, Muscle Sympathetic Nerve Activity; HRV, heart rate variability; CPAP, fixed continuous positive pressure; APAP, auto-adjusting continuous positive pressure.

1		
2		
3	1	
4		
5	2	<u>References</u>
6 7		
/ 0	3	1. Baguet JP. Barone-Rochette G. Tamisier R. Levy P. Pepin JL. Mechanisms of cardiac dysfunction in
0 0	4	obstructive sleep apnea. Nature reviews Cardiology. 2012;9(12):679-88.
10	5	2. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk
11	6	factor for stroke and death. The New England journal of medicine. 2005;353(19):2034-41.
12	7	3. Gami AS, Olson Ej Fau - Shen WK, Shen Wk Fau - Wright RS, Wright Rs Fau - Ballman KV, Ballman Kv
13	8	Fau - Hodge DO, Hodge Do Fau - Herges RM, et al. Obstructive sleep apnea and the risk of sudden cardiac
14	9 10	death: a longitudinal study of 10,701 adults. (1558-3597 (Electronic)).
15	10	4. Sundstrom J, Neal B. Effects of Blood Pressure Reduction in Mild Hypertension. Annals of internal
16	11	Medicine, 2015;163(1):67-8.
17	12	5. Diager LF, Micevoy RD, Barber, Lorenzi-Fillio G, Reuline S, Initiative I. Sleep Aprilea and Cardiovascular Disease: Lessons From Recent Trials and Need for Team Science, Circulation, 2017:136(10):1840-50
18	14	6 Javaheri S. Barhe F. Campos-Rodriguez F. Dempsey JA. Khavat R. Javaheri S. et al. Sleen Annea: Types
19	15	Mechanisms, and Clinical Cardiovascular Consequences. J Am Coll Cardiol. 2017:69(7):841-58.
20	16	7. Lim SS. Vos T. Flaxman AD. Danaei G. Shibuya K. Adair-Rohani H. et al. A comparative risk assessment
21	17	of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010:
22	18	a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224-60.
23	19	8. Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Cowan MJ, et al. National, regional, and global
24	20	trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and
25	21	epidemiological studies with 786 country-years and 5.4 million participants. Lancet. 2011;377(9765):568-77.
26	22	9. Whelton Pk Fau - Carey RM, Carey Rm Fau - Aronow WS, Aronow WS, Casey DE, Jr., Collins KJ,
27	23	Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline
28	24	for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the
29	25	American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. LID -
30	20	HYP.00000000000000005 [pii] LID - 10.1161/HYP.0000000000000005 [doi] FAU - Wheiton, Paul K. (1524-4563
31	27	(Electronic)).
32	20	disordered breathing and bypertension. The New England journal of medicine. 2000;342(19):1378-84
33	30	11. Narkiewicz K. Somers VK. Obstructive sleep appea as a cause of neurogenic hypertension. Current
34	31	hypertension reports, 1999:1(3):268-73.
35	32	12. Levy P, Kohler M, McNicholas WT, Barbe F, McEvoy RD, Somers VK, et al. Obstructive sleep apnoea
36	33	syndrome. Nature reviews Disease primers. 2015;1:15015.
3/	34	13. Tamisier R, Pepin JL, Remy J, Baguet JP, Taylor JA, Weiss JW, et al. 14 nights of intermittent hypoxia
38	35	elevate daytime blood pressure and sympathetic activity in healthy humans. The European respiratory journal.
29 40	36	2011;37(1):119-28.
40 //1	37	14. Tamisier R, Tan CO, Pepin JL, Levy P, Taylor JA. Blood Pressure Increases in OSA due to Maintained
41	38	Neurovascular Sympathetic Transduction: Impact of CPAP. Sleep. 2015;38(12):1973-80.
42 43	39	15. Tamisler R, Levy P, Pepin JL. Do patients with obstructive sleep aphoea deserve new dedicated
4J 44	40 //1	anunyperiensive strategies? morax. 2017;72(0):495-7.
45	41	annea The Journal of clinical investigation 1995;96(4):1897-904
46	43	17. Gilmartin GS. Lynch M. Tamisier R. Weiss JW. Chronic intermittent hypoxia in humans during 28 nights
47	44	results in blood pressure elevation and increased muscle sympathetic nerve activity. American journal of
48	45	physiology Heart and circulatory physiology. 2010;299(3):H925-31.
49	46	18. Shoemaker JK, Klassen SA, Badrov MB, Fadel PJ. Fifty years of microneurography: learning the
50	47	language of the peripheral sympathetic nervous system in humans. J Neurophysiol. 2018;119(5):1731-44.
51	48	19. Hering D, Kucharska W, Chrostowska M, Narkiewicz K. Age-dependent sympathetic neural responses
52	49	to ss1 selective beta-blockade in untreated hypertension-related tachycardia. Blood Press. 2018;27(3):158-65.
53	50	20. Pedroso D, Nunes AR, Diogo LN, Oudot C, Monteiro EC, Brenner C, et al. Hippocampal neurogenesis
54	51	response: What can we expect from two different models of hypertension? Brain Res. 2016;1646:199-206.
55	52	21. Carison JT, neuner J, Elam IVI, Ejnell H, Sellgren J, Wallin BG. Augmented resting sympathetic activity in awake nationate with obstructive cloop appear. Chest, 1002:102(6):1762.9
56	22	awake patients with obstructive sleep appled. Chest. 1995,105(0).1703-8.
57		
58		21
59		For poor roviou only http://hmiopon.hmi.com/rite/shout/ruidelines.uktral
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

22. Usui K, Bradley TD, Spaak J, Ryan CM, Kubo T, Kaneko Y, et al. Inhibition of awake sympathetic nerve activity of heart failure patients with obstructive sleep apnea by nocturnal continuous positive airway pressure. J Am Coll Cardiol. 2005;45(12):2008-11. Narkiewicz K, Kato M, Phillips BG, Pesek CA, Davison DE, Somers VK. Nocturnal continuous positive 23. airway pressure decreases daytime sympathetic traffic in obstructive sleep apnea. Circulation. 1999;100(23):2332-5. 24. Waradekar NV, Sinoway LI, Zwillich CW, Leuenberger UA. Influence of treatment on muscle sympathetic nerve activity in sleep apnea. American journal of respiratory and critical care medicine. 1996;153(4 Pt 1):1333-8. 25. Bratton DJ, Gaisl T, Wons AM, Kohler M. CPAP vs Mandibular Advancement Devices and Blood Pressure in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta-analysis. Jama. 2015;314(21):2280-93. Bratton DJ, Stradling JR, Barbe F, Kohler M. Effect of CPAP on blood pressure in patients with minimally 26. symptomatic obstructive sleep apnoea: a meta-analysis using individual patient data from four randomised controlled trials. Thorax. 2014;69(12):1128-35. Montesi SB, Edwards Ba Fau - Malhotra A, Malhotra A Fau - Bakker JP, Bakker JP. The effect of 27. continuous positive airway pressure treatment on blood pressure: a systematic review and meta-analysis of randomized controlled trials. (1550-9397 (Electronic)). Alajmi M, Mulgrew At Fau - Fox J, Fox J Fau - Davidson W, Davidson W Fau - Schulzer M, Schulzer M 28. Fau - Mak E, Mak E Fau - Ryan CF, et al. Impact of continuous positive airway pressure therapy on blood pressure in patients with obstructive sleep apnea hypopnea: a meta-analysis of randomized controlled trials. (0341-2040 (Print)). Bazzano LA, Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive airway pressure on 29. blood pressure in obstructive sleep apnea. Hypertension. 2007;50(2):417-23. 30. Haentjens P, Van Meerhaeghe A Fau - Moscariello A, Moscariello A Fau - De Weerdt S, De Weerdt S Fau - Poppe K, Poppe K Fau - Dupont A, Dupont A Fau - Velkeniers B, et al. The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-controlled randomized trials. (0003-9926 (Print)). 31. McDaid C, Duree KH, Griffin SC, Weatherly HL, Stradling JR, Davies RJ, et al. A systematic review of continuous positive airway pressure for obstructive sleep apnoea-hypopnoea syndrome. Sleep medicine reviews. 2009;13(6):427-36. 32. Martinez-Garcia MA, Capote F, Campos-Rodriguez F, Lloberes P, Diaz de Atauri MJ, Somoza M, et al. Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial. Jama. 2013;310(22):2407-15. Barbe F, Duran-Cantolla J, Sanchez-de-la-Torre M, Martinez-Alonso M, Carmona C, Barcelo A, et al. 33. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. Jama. 2012;307(20):2161-8. Pepin JL, Timsit JF, Tamisier R, Levy P. Is CPAP effective in reducing blood pressure in minimally 34. symptomatic obstructive sleep apnoea? Thorax. 2014;69(12):1068-70. Sanders MH, Montserrat JM, Farre R, Givelber RJ. Positive pressure therapy: a perspective on evidence-based outcomes and methods of application. Proceedings of the American Thoracic Society. 2008;5(2):161-72. 36. Hertegonne K, Bauters F. The value of auto-adjustable CPAP devices in pressure titration and treatment of patients with obstructive sleep apnea syndrome. Sleep medicine reviews. 2010;14(2):115-9. 37. Morgenthaler TI, Aurora RN, Brown T, Zak R, Alessi C, Boehlecke B, et al. Practice parameters for the use of autotitrating continuous positive airway pressure devices for titrating pressures and treating adult patients with obstructive sleep apnea syndrome: an update for 2007. An American Academy of Sleep Medicine report. Sleep. 2008;31(1):141-7. Won CH. Man Versus Machine. Journal of clinical sleep medicine : JCSM : official publication of the 38. American Academy of Sleep Medicine. 2017;13(2):167-8. 39. Ayas NT, Patel SR, Malhotra A, Schulzer M, Malhotra M, Jung D, et al. Auto-titrating versus standard continuous positive airway pressure for the treatment of obstructive sleep apnea: results of a meta-analysis. Sleep. 2004;27(2):249-53. 40. Fuchs FS, Wiest GH, Frank M, Harsch IA, Schahin SP, Hahn EG, et al. Auto-CPAP therapy for obstructive sleep apnea: induction of microarousals by automatic variations of CPAP pressure? Sleep. 2002;25(5):514-8. 41. Marrone O, Insalaco G, Bonsignore MR, Romano S, Salvaggio A, Bonsignore G. Sleep structure correlates of continuous positive airway pressure variations during application of an autotitrating continuous For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml 

<ul> <li>positive airway pressure machine in patients with obstructive sleep apnea syndrome. Chest. 2002;121(3):739-6.</li> <li>Patruno V, Aioff S, Costantino G, Murgia R, Selmi C, Malliani A, et al. Fixed and autoadjusting continuous positive airway pressure treatments are not similar in reducing cardiovascular risk factors in patients with obstructive sleep apnea. Chest. 2007;131(5):1329.</li> <li>Penin JL, Tamiser R, Baguet JP, Lepaulle B, Arbit F, Arnol N, et al. Fixed pressure CPA versus auto-adjusting CPAP comparison of efficacy on blood pressure in obstructive sleep apneae. a randomised clinical trib. Theore J. Silegol PAP. Comparison of efficacy on blood pressure in obstructive sleep apneae are nulticonstip with nocturnal sympathetic activity. Clinical and experimental hypertension. 2013;26(3):373-80.</li> <li>Mest SD, Jones DK, Stradling JR. Comparison of three ways to determine and deliver pressure during nasiCAP therapy to robstructive sleep apneae. Thorax. 2006;3(3):226-31.</li> <li>Tamasulu L, Epotturk PO, Sokuci SN, Dalar L, Alta S. Improving Heart rate variability in sleep apnea patients: afferences in treatment with auto-titrating positive airway pressure (ArAP) revises conventional CPAP. Lung. 2010;184(4):315-20.</li> <li>Tamasulu L, Epotturk PO, Sokuci SN, Dalar L, Alta S. Improving Heart rate variability in deep apnea patients: afferences in treatment with auto-titrating positive airway pressure (ArAP) revises conventional CPAP. Lung. 2010;184(4):315-20.</li> <li>Tama CO, Tamisler K, Hamner LW, Taylor JA. Automated quantification of sympathetic bat-by-beat activity, independent of signal quilt. Journal of application for the management of attrait hypertension. The Task force for the management of attrait hypertension of the turopean Society of Cardiology and the European Society of Hypertension. The Task force for the management of Attraital Hypertension. The Task force of the management of Attraital Hyperetension. 2013;3(2):103-30.</li> <li>Tama CO, Tamisler K</li></ul>	1		
<ul> <li>prove a may be sub-matime in proving software symplex symplex proving symplex software software symplex software software software symplex software softwar</li></ul>	2	1	positive airway process maching in patients with obstructive clean appear syndrome. Chect. 2003;121(2);750
<ol> <li>2. Patruco V. Abdilf S. Costantino G. Murgia R. Semit. C. Malliani A. et al. Fixed and autoalising ontinuous positive airway persuit retraments and to inflain in reducing cardiovascular risk factors in patients with obstructive sieep apnes. Chest. 2007;131(9):1399-9</li> <li>3. Patruco V. Abdilf S. Costantion G. Pest. 2007;131(9):1399-9</li> <li>4. Bioch KS. Huber F. Furiari M. Latshang TD. Lo Cacita CM. Nuschaumer-Ochner Y. et al. Autoadjusted versus fixed CMP for obstructive sieep apnesa: a multicentre, randomised equivalence trial. Thorax. 2017.</li> <li>4. Marce O. Sakaggio A. Buc Al. Bonamo A. Alteccobino L. Insistaro G. et al. Autoadjusted versus fixed CMP for obstructive sieep apnesa: inductorship with necturnal sympathetic activity. Clinical and experimental hyportarismic 2013;63(3):73-80.</li> <li>4. Marce D. Sakaggio A. Buc Al. Bonamo A. Alteccobino L. Insistaro G. et al. Acute effects of autoratic and fixed CMP in obstructive sieep apnesa: relationship with necturnal sympathetic activity. Clinical and experimental hyportarismic 2013;13(6):137-80.</li> <li>4. Marsabu L. Pootuk PO, Sokuca SN, Dalar L, Altin S. Improving iterat rate variability in sieep apnes patients with obstructive sieep apnesa. Inforax. 2006;6(3):226-51.</li> <li>4. Datos UM, Anew method for measuring dayline sieepiness: the Exporth sieepiness calls. Beep. 1931;24(5):245-51.</li> <li>5. Marmer JW, Tafori A. Automated quantification of sympathetic baet by beat activity, independent of agnagliautic yournal of applied physiology. 2001;9(1):11:19-20.</li> <li>5. Marmer ZW, Tafori A. Automated quantification of sympathetic neurosscular transduction in thumas. RNon 2013;8(1):01:537-50.</li> <li>5. Martine G. Chainess M. Kabadi Roself, Aziti M. Burnier M. et al. 2018 ESC/SIN Educiding for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of thypertension. The Task Force for the Ma</li></ol>	3	2	67
<ul> <li>continuous positive airway pressure treatments are not similar in reducing cardiovascular risk factors in patients with obstructive sleep appeae. Checz 2007;111(5):1399.</li> <li>Feprin II, Tamiser R, Baguel PJ, Lepaulle B, Arbib F, Arnol N, et al. Fixed-pressure CAPA versus auto-adjusting GPA comparison on blood pressure in obstructive sleep appeae. a randomised equivalence trial. Thorax. 2015;71(8):726-33.</li> <li>Buch KS, Zhang MD, Labor J, Nethal F, Arnol N, et al. Streed-pressure CAPA versus functional adjusting GPA comparison on blood pressure in obstructive sleep appeae. a functional sympathetic activity. Clinical and experimental hypertension. 2011;33(6):372-80.</li> <li>Marrone O, Salvagio A, Buc AL, Bonamo A, Riccabono L, Insaleco S, et al. Biolog pressure during neal CAPA therapy for obstructive sleep appeae. Thorax. 2005;61(3):226-31.</li> <li>Marrone O, Solvagio D, Nordalin J, Altin S. Impoving Heat Tate variability in sleep appea patients: differences in treatment with auto-treating positive airway pressure (APAP) versus controlling to CPAP. Ling. 2010;88(4):376-30.</li> <li>Bartuno V, Tobaldini F, Bianchi AM, Mendez MO, Coletti O, Costantino G, et al. Actue effects of autoadjusting and field contrulous positive airway pressure treatments on cardiorespiratory coupling in obsec patients with obstructive sleep appeae. European journal of internal medicine. 2014;25(2):164-8.</li> <li>Don Homer JW, Taylor JA. Automated quantification of sympathetic best-by-beat activity, independent of agalogai U, Journal of applied physiology. 2001;11(3):1199-206.</li> <li>Con Tanliser H, Jamer JW, Taylor JA. Automated quantification of sympathetic neuroascular transduction in humans. PloS one. 2013;8(1):63763.</li> <li>Sommer JW, Taylor JA. Automated quantification of sympathetic best-by-beat activity, independent of agalogai U, Journal of applied physiology. 2001;91(3):1199-206.</li> <li>Sommer JW, Taylor JA. Automated quantification of sympathetic best-by-beat acti</li></ul>	4	3	42. Patruno V. Aiolfi S. Costantino G. Murgia R. Selmi C. Malliani A. et al. Fixed and autoadjusting
<ul> <li>patients with obstructive siege apres. Chest. 2007;131(9):1393-9.</li> <li>H. Samsier R. Baguet P. Levalle R. Arbib F. Ali Keek pressure CPAP versus auto-adjusting CPAP: comparison of efficacy on blood pressure in obstructive siege aproce. a randomised clinical trite. Thorax. 2017;71(8):526-53.</li> <li>M. Bioch KF, Huber F, Furian M, Latshang TD, Lo Cascio CM, Nusbanumer-Ochsner Y, et al. Autoadjusting Varsus fields CPAP for obstructive siege aproare radiationship with noctural sympathetic activity. Clinical and experimental hypertension. 2011;33(6):377-80.</li> <li>M. Warrone O, Salvaggio A, Bue AJ, Bonamon A, Riccobno L, Insalaco G, et al. Blood Pressure changes after automatic and fixed CPAP in obstructive siege appare radiationship with noctural sympathetic activity. Clinical and experimental hypertension. 2011;33(6):377-80.</li> <li>M. Warrone O, Salvaggio A, Bue AJ, Bonamon A, Mcodz ND, Coletti D, Costantino G, et al. Acute effects of autosljusting and fixed continuous positive airway pressure (APAP) versus conventional CPAP therapy for obstructive eleop appres. Thorax. 2006;61(1):226-31.</li> <li>P. Patruno V, Tobaldini F, Bianchi AM, Mendez MD, Coletti D, Costantino G, et al. Acute effects of autosljusting and fixed continuous positive airway pressure treatments on cardiorespiratory coupling in obese patients: with obstructive seeg appres. Teoropean Journal of Internal medicine. 2014;23(1):164-8.</li> <li>J. Inte O, Tobaldini F, Bianneri JM, Taylor JA. Characterizing sympathetic baet-by-beat activity, independent of angle appres. Thoray and the European Society of Hypertension of the European Society of Hypertension. The Task Force for the management of arterial hypertension. 2013;36(1):199-306.</li> <li>M. Manada G, B Backer G, Dominicata K, Clikova F, Eard A, SM Sooring Manual Updates for the Management of Arterial hypertension. 2018;36(1):1993-2041.</li> <li>M. Manada G, Spiereng W, Agabit Rosel F, Azita M, Burnier M, et al. 2018 ESC/ESH Guidelines of the</li></ul>	5	4	continuous positive airway pressure treatments are not similar in reducing cardiovascular risk factors in
<ul> <li>4. Pepin JL Tamisier R, Baguet JP, Lepaulle B, Atbib F, Arnol N, et al. Fixed-pressure GAP versus auto-adjusting CPAP: comparison of efficacy on blood pressure in obstructure sleep apneae, a randomised dinical trial. Thorax. 2016;71(8):726-33.</li> <li>4. Bioto KE, Huber F, Furiar M, Listaharg TD, Lo Castio CM, Nusshaumer-Ochsner Y, et al. Autoadjusted wirsus fixed CPAP for obstructive sleep apnea: relationship with necturnal sympathetic activity. Clinical and experimental hypertension. 2011;32(6):372-80.</li> <li>4. West SD, Jones DG, Strading JR. Comparison of threas ways to determine and deliver pressure during neasil CPAP therapy for obstructive sleep apnea: relationship with necturnal sympathetic activity. Clinical and experimental hypertension. 2011;32(6):372-80.</li> <li>4. Nest SD, Jones DG, Strading JR. Comparison of threas ways to determine and deliver pressure during neasil CPAP therapy for obstructive sleep apnea: neasily the analysis of the availability in sleep apnea patients: differences in treatment with auto-litrating positive airway pressure (PAPA) versus conventional CPAP. Ling. 2010;188(4):315-50.</li> <li>4. Batruno V, Tobaldin E, Bianchi AM, Mendez NO, Coletti D, Costantino G, et al. Acute effects of autoadjusting and fined continuous positive airway pressure treatments on carolacy sciences. Step: 2014;25(2):168-05.</li> <li>5. Din SMW. A new method for measuring daytima telepiness: the Epworth sleepiness cale. Step: 1931;4(6):540-5.</li> <li>5. Anton Co, Tamisfer A, Hammer JW, Hayola JA. Automaterial sympathetic beat-by-beat activity, independent of signal quality. Journal of applied physiology. 2001;91(3):1199-20.</li> <li>5. Millins B, Mandoi G, Spieler QW, Agabili Rost E, Azili M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of atreial hypertension of the European Society of Cardiology at the European Society of Cardi</li></ul>	6	5	patients with obstructive sleep apnea. Chest. 2007;131(5):1393-9.
<ul> <li>adjusting CAP: comparison of efficacy on blood pressure in obstructive sleep apnee, a randomised clinical true. Thors. 2016;71(8):276-33.</li> <li>H. Bioch KF, Huber F, Furiam M, Latshang TD, Lo Castio CM, Nusbhaumer-Ochsner Y, et al. Auto-adjusted versus filed CAPA for obstructive sleep apnea: relationship with notcurnal sympathetic activity. Clinical and egenimental hypertension 2011;33(6):373-80.</li> <li>K. West SD, Jones DB, Stradling JA. Comparison of three ways to determine and deliver pressure during nasal CAPA therapy for obstructive sleep apnea. Treat. 2006;13(1):226-31.</li> <li>K. Tarsulu L, Eporturk PO, Sokucu SD, Olar L, Altin S. Improving Heart rate variability in sleep apnea patients: differences in treatement with auto-aria analy ensway pressure (PAPA) versus conventional CPAP. Lung. 2010;188(4):315-20.</li> <li>R. Partuno V, Tobaldin E, Bianchi AM, Mendez MO, Coletti O, Costantino G, et al. Acute effects of autoadjusting and fixed continuous positive airway pressure treatments on cardiorespiratory coupling in obsee patients: with obstructive seep apnee. Lirocapa Journal of internal medicine. 2010;125(2):154-8.</li> <li>Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540-5.</li> <li>Tan CQ, Tamisler R, Hammer JW, Taylor JA. Characterluing sympathetic neurovascular transduction in humans. Pioto ne. 2013;8(1):633-70.</li> <li>Tan CQ, Tamisler R, Hammer JW, Taylor JA. Characterluing sympathetic neurovascular transduction in humans. Pioto neuroscular transduction of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Lardiology and the European Society of Hypertension: 1007 European Society of Hypertension: 1007 European Society of Hypertension: 2007;20(5)(4)(4)(4)(4)(4)(4)(4)(4)(4)(4)(4)(4)(4)</li></ul>	/	6	43. Pepin JL, Tamisier R, Baguet JP, Lepaulle B, Arbib F, Arnol N, et al. Fixed-pressure CPAP versus auto-
<ul> <li>trial. Thorax. 2016;71(8):726-33.</li> <li>44. Bioch KF, Huber F, Furiar M, Listshang TD, Lo Casclo CM, Nusshaumer-Ochsner Y, et al. Autoadjusted versus fixed CPAP for obstructive sleep apneas: relationship with nectural sympathetic activity. Clinical and experimental hypertension. 2011;33(6):373-80.</li> <li>45. Marone O, Salvaggio A, Bue AL, Bonamo A, Riczobano L, Insalce O, et al. Blood pressure during neasa CPAP therapy for obstructive sleep apneas: relationship with nectural sympathetic activity. Clinical and experimental hypertension. 2011;33(6):373-80.</li> <li>46. West SD, Jones DB, Stradling JR. Comparison of Three ways to determine and deliver pressure during neasa CPAP therapy for obstructive sleep apneas. Thorax. 2006;51(3):226-31.</li> <li>47. Karasulu L, Eporturk PO, Sokuca SD, Joalr J, Altins. Limproving Heart rate variability in sleep apnea patients: differences in treatment with auto-titrating positive airway pressure (APAP) versus conventional CPAP. Ling. 2010;388(4):315-50.</li> <li>48. Patruno V, Tobaldini E, Bianchi AM, Mendez MO, Coletti O, Costantino G, et al. Acute affects of autoadjusting and fixed continuous positive airway pressure incentents on cardiorespiratory coupling in obese patients with obstructive sleep apnea. European journal of internal medicine. 2014;25(2):164-8.</li> <li>49. Johns MW. A new method for measaring dayrime sleepiness: the Epworth sleepiness cale. Sleep. 1991;14(6):540-5.</li> <li>50. Hamore JW, Taylor JA. Automated quantification of sympathetic beat-by beat activity, independent of signal quality. Journal of applied physiology. 2001;91(3):1199-206.</li> <li>51. Tan CO, Comiser R, Hamare JW, Taylor JA. Chrows R, Fagard R, Germano G, et al. 2018 EC/SHS Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension. The Task Force for the Management of arterial hypertension of the European Society of Hypertension. The Task Forc</li></ul>	8	7	adjusting CPAP: comparison of efficacy on blood pressure in obstructive sleep apnoea, a randomised clinical
<ul> <li>9</li> <li>44. Bloch KE, Huber F, Furian M, Latshang TD, Lo Cascio CM, Nusshaumer-Othsner Y, et al. Autoadjusted versus fixed CPAP for obstructive sleeg apona: randincient randomised quivalence trial. Thorax. 2017.</li> <li>45. Marrone O, Salvaggio A, Bue AL, Bonamo A, Riccobone L, Insalaco G, et al. Blod or Passure changes after automatic and fixed CPAP in obstructive sleeg apane: rationship with noctural sympathetic activity. Clinical and experimental hypertension. 2011;33(6):373-80.</li> <li>46. West SD, Jones DR, Stradling JR. Comparison of three ways to determine and deliver pressure changes after automatic and fixed CPAP in obstructive sleep aponea. Thorax. 2006;61(3):226-31.</li> <li>47. Karasulu L, Epaztur PO, Sokucu SN, Dalar L, Altin S. Improving Heart rate variability in sleep apone patients: differences in treatment with auto-citating positive airway pressure (PAPA) versus conventional CPAP. Lung. 2010;188(4):315-20.</li> <li>48. Patruno V, Tobaldin E, Blanchi AM, Mendez MO, Coletti O, Costantino G, et al. Acute effects of autoadjusting and fixed continuous positive airway pressure treatments on cardiorespiratory coupling in obsee patients with obstructive sleep apone. Thorax. 2006;61(3):226-31.</li> <li>49. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540-5.</li> <li>50. Hammer JW, Taylor JA. Automated quantification of sympathetic beat-by-beat activity, independent of signal quality. Journal of apolice physiology. 2001;13(3):1199-206.</li> <li>51. Tan CO, Tamisier R, Hammer JW, Taylor JA. Characterizing sympathetic neurovascular transduction in humans. Prof. on: 2013;8(1):16:3376.</li> <li>52. Williams B, Mancia G, Spiering W, Agabiti Rosel E, Azil M, Burnier M, et al. 2018 EC/SUSH Guiddlines for the faungement of arterial hypertension. 2018;36(10):1953-2041.</li> <li>53. Mancia G, De Backer G, Dominicza A, Cliftovia R, Egazd R, Germano G, et al. 2007 Guidelines for the Management of Ar</li></ul>	9	8	trial. Thorax. 2016;71(8):726-33.
<ul> <li>versus fixed CPAP for obstructive sleep apnea: a multicentre, randomised equivalence trial. Thorax. 2017.</li> <li>45. Marrone O, Salvaggio A, Bus AL, Bonamo A, Riccobon L, Insalaco G, et al. Blood pressure changes after automatic and fixed CPAP in obstructive sleep apnea: relationship with nocturnal sympathetic activity. Clinicial and experimental hypertension. 2011;33(6):373-80.</li> <li>46. West SD, Jones DB, Stradling JR. Comparison of three ways to determine and deliver pressure during patients: differences in treatment with auto-litrating positive airway pressure (APAP) versus conventional CPAP. Ling. 2010;188(4):355-20.</li> <li>48. Patruno V, Tobaldini E, Bianchi AM, Mendez MO, Coletti O, Costantino G, et al. Acute effects of satubadjusting and fixed continuous positive airway pressure treatments to acidorespiratory coupling in obset patients: with obstructive sleep apnea. European journal of internal medicine. 2014;25(2):164.8.</li> <li>49. Johns MW. A new method for measuring daytime sleepiness: the Eµworth sleepiness scale. Sleep. 1991;14(6):540-5.</li> <li>50. Hammer JW, Taylor JA. Automated quantification of sympathetic beat-by-beat activity, independent of signal quality. Journal of applied physiology. 2001;91(3):1199-206.</li> <li>51. Tar O, Tarnisier R, Hamner JW, Taylor JA. Characterizing sympathetic neurovascular transduction in humans. PloS one. 2013;8(1):e5376.</li> <li>52. Williams B, Manda G, Spiering W, Agabtit Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the maagement of arterial hypertension. The Task Force for the maagement of arterial hypertension. The Task Force for the Management of Arterial hypertension. The Task Force for the Management of Arterial hypertension. 2013;8(1):1937.</li> <li>53. Marcia G, De Backer G, Dominica A, Clittova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial hypertension. The Task Force for the Management of Arterial hypertension. 2013;8(1):1937.</li> <li>54. Be</li></ul>	10	9	44. Bloch KE, Huber F, Furian M, Latshang TD, Lo Cascio CM, Nussbaumer-Ochsner Y, et al. Autoadjusted
<ul> <li>45. Marrone O, Salvagelo A, Bue AL, Bonanno A, Riccobono L, Insalaco G, et al. Bood pressure changes after automatic and fixed CPAP in obstructive sleep apnea: relationship with noturnal sympathetic activity. Clinical and experimental hypertension. 2011;33(6):373-80.</li> <li>46. West SD, Jones DB, Stradling JR. Comparison of three ways to determine and deliver pressure during nasal CPAP therapy for obstructive sleep apnea. Thorax. 2006;61(3):226-31.</li> <li>47. Karasulu L, Epozturi PO, Sokucu SN, Dalar L, Alin S. Imyoring iteart rate variability in sleep apnea patentis: differences in treatment with auto-intraing postive airway pressure (APAP) versus conventional CPAP. Lung. 2010;188(4):315-20.</li> <li>48. Patruno V, Toabaidi F, Bianchi AM, Mendez MO, Coletti O, Costantino G, et al. Acute effects of autoadjusting and fixed continuous positive airway pressure treatments on cardiorespiratory coupling in obese patients: with obstructive sleep apnea. Improve Jones 2019;21(4):6540-5.</li> <li>50. Hammer JW, Taylor JA. Automated quantification of sympathetic hear-by-beat activity, independent of signal quality. Journal of applied physiology. 2001;91(3):1199-206.</li> <li>51. Tan CO, Tamišler R, Hamner JW, Taylor JA. Characterizing sympathetic neurovascular transduction in humans. PloS one. 2013;8(1):8378-90.</li> <li>52. Milliams B, Manacia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. The Task Force for the management of Arterial hypertension of the European Society of Cardiology and the European Society of Hypertension of the European Society of Hypertension. The Task Force for the management of Arterial hypertension of the European Society of Cardiology and the European Society of Hypertension of the European Society of Hypertension. The Task Force for the management of Arterial hypertension of the European Society o</li></ul>	11	10	versus fixed CPAP for obstructive sleep apnoea: a multicentre, randomised equivalence trial. Thorax. 2017.
12       after automatic and fixed CPAP in obstructive sleep apnea: relationship with nocturnal sympathetic activity.         13       46. West SD, Jones DR, Stradling JR. Comparison of three ways to determine and deliver pressure during nasa (CPAP therapy for obstructive sleep apnea. Thera: 2006;51(3):226-31.         14       46. West SD, Jones DR, Stradling JR. Comparison of three ways to determine and deliver pressure during nasa (CPAP therapy for obstructive sleep apnea. Thera and the approxement of activity and pressure (APAP) versus conventional CPAP. Lung. 2010;188(4):315-20.         15       47. Karasulu L, Epozturk PO, Sokucu SN, Dalar L, Altin S. Improving Heart rate variability in sleep apnea patients: differences in treatment on with auto-titrating positive airway pressure (APAP) versus conventional CPAP. Lung. 2010;188(4):315-20.         16       48. Patruno V, Tobaldini E, Bianchi AM, Mendez MO, Coletti O, Costantino G, et al. Acute effects of autoadjusting and fixed continuous positive airway pressure treatments on cardiorespiratory coupling in obsee patients with obstructive sleep apnea. European journal of internal medicine. 2014;25(2):164-8.         14       49. Johon SWA. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540-5.         15       50. Hamner JW, Taylor JA. Automated quantification of sympathetic neurowascular transduction in humas. PloS one. 2013;8(1):e53769.         16       51. Tan CO, Tamisier R, Hammer JW, Taylor JA. Characterizing sympathetic neurowascular transduction in humas. PloS one. 2013;8(1):e53769.         16       52. Williams B, Mancia G, Spiering W, Agabit Roseit E, Azizi M, Burnier M, et al. 2017 Guideli	12	11	45. Marrone O, Salvaggio A, Bue AL, Bonanno A, Riccobono L, Insalaco G, et al. Blood pressure changes
<ul> <li>Clinical and experimental hypertension. 2011;33(6):373-80.</li> <li>Guincal and experimental hypertension. Thorax. 2006;61(3):226-31.</li> <li>Mest SD. Jones DBS, Stradling IR, Comparison of three ways to determine and deliver pressure during natal CPAP therapy for obstructive sleep apnoea. Thorax. 2006;61(3):226-31.</li> <li>Aransalu C, Eportur PO, Stoucit Ve, OS Sucue SN, Dalar L, Athin S. Improving Heart rate variability in sleep apnea pratents: differences in treatment with auto-titrating positive airway pressure (APAP) versus conventional CPAP. Lung. 2010;188(4):315-20.</li> <li>Bartuno V, Tobaldini F, Bianchi AM, Mendez MO, Coletti O, Costantino G, et al. Acute effects of autoadjusting and fixed continuous positive airway pressure treatments on cardioresprintery coupling in obsese patients: with obstructives sleep apneae. European journal of internal medicine. 2014;25(2):164-8.</li> <li>Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540-5.</li> <li>Mamner JW, Taylor JA. Automated quantification of sympathetic hear-by-beat activity, independent of signal quality. Journal of applied physiology.2001;91(3):1199-206.</li> <li>Tara CO, Tamisier R, Hammer JW, Taylor JA. Characterizing sympathetic neurovascular transduction in humans. Plo5 one. 2013;8(1):853769.</li> <li>Williams B, Mandia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of 1007 Guidelines for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of 2007 Guidelines for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of 2007 Guidelines for the Management of Arterial Hyp</li></ul>	13	12	after automatic and fixed CPAP in obstructive sleep apnea: relationship with nocturnal sympathetic activity.
<ul> <li>46. West SD, Jones DR, Stradling JR. Comparison of three ways to determine and deliver pressure during nasal CPAP therapy for obstructive siles papnea. Thorax. 2006;61(3):226-31.</li> <li>47. Karasulu L, Epotturk PO, Sokucu SN, Dalar L, Altin S. Improving Hearr tate variability in sleep apnea patients: differences in treatment with uato-titrating positive airway pressure (APAP) versus conventional CPAP. Lung. 2010;188(4):135-20.</li> <li>48. Patrano V, Tobaldini E, Blanchi AM, Mendez MO, Coletti O, Costantino G, et al. Acute effects of autoadjusting and fixed continuous positive airway pressure treatments on cardiorespiratory coupling in obese patients with obstructive sleep apnea. European journal of internal medicine. 2012;5(2):164-8.</li> <li>49. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540-5.</li> <li>50. Hanner JW, Taylor JA. Automated quantification of sympathetic hear-by-beat activity, independent of signal quality. Journal of applied physiology. 2001;91(3):1199-206.</li> <li>51. Tan CO, Tamisier R, Hamner JW, Taylor JA. Characterizing sympathetic neurovascular transduction in humans. Plo5 one. 2013;8(1):453769.</li> <li>52. Williams B, Mancia G, Spiering W, Agabiti Rosel F, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension. The Task Force for the management of arterial hypertension. 2018;8(10):1953-2041.</li> <li>53. Mancia G, De Backer G, Dominicax A, Girkowa R, Fagard R, Germano G, et al. 2007 Guidelines for the furopean Society of Hypertension. 2007;6(5):1105-87.</li> <li>54. Berry RB, Brooks R, Gamaldo C, Harding SM, Lloyd RM, Quan SF, et al. ASM Soring Manual Updates for 2017;14(5):665-6.</li> <li>55. Shittencour LR, Scheck R, Jurik S, Peres C, Togiro SM, Baganto MC, et al. The variability of the apneea-hypopneea index. Journal of finker Specins M, Baganta MC, et al. The variability o</li></ul>	14	13	Clinical and experimental hypertension. 2011;33(6):373-80.
<ul> <li>Isad CPAP therapy for obstructive sleep apneas. Thorax. 2005;61(3):226-31.</li> <li>A. Karsalu L, Eporturk PO, Sokucu SN, Dalar L, Ahltin S. Improving Heart rate variability in sleep apnea patients: differences in treatment with auto-titrating positive airway pressure (APAP) versus conventional CPAP. Lung, 2010;188(3):155-20.</li> <li>B. Patruno V, Tobaldini E, Blanchi AM, Mendez MO, Coletti O, Costantino G, et al. Acute effects of autoadjusting and fixed continuous positive airway pressure (APAP) versus conventional CPAP. Lung, 2010;188(6):155-05.</li> <li>Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540-5.</li> <li>Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540-5.</li> <li>Tan CQ, Tamisier R, Hamner JW, Tayfor JA. Automated quantification of sympathetic beat-by-beat activity, independent of signal quality. Journal of applied physiology. 2001;91(3):1199-206.</li> <li>Tan CQ, Tamisier R, Hamner JW, Tayfor JA. Characterizing sympathetic neurovascular transduction in humans. PloS one. 2013;8(1):63769.</li> <li>Mullians B, Mancia G, Spiering W, Agabit Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension. The Task Force for the management of arterial hypertension. 2018;36(10):1953-2041.</li> <li>Mancia G, De Backer G, Dominicak A, Cirkova R, Fagard R, Germano G, et al. 2007 Guidelines for the European Society of Hypertension. 2017;35(5):1105-87.</li> <li>Mancia G, De Backer G, Dominicak A, Cirkova R, Fagard R, Germano G, et al. 2007 Guidelines for 2017 (Version 2.4). Journal of clinical sleep medicine: 215M : official publication of the American Academy of Sleep Medicine. 2017;13(5):656-6.</li> <li>Mitte Li, Upons D, Yadolishi A, Kan CM, Bradley TD. Night-to-night variability in obstructive sleep apneas everity: relationship to overni</li></ul>	15	14	46. West SD, Jones DR, Stradling JR. Comparison of three ways to determine and deliver pressure during
<ul> <li>41. Karasulu L, Epstuck PO, Sokuca SN, Dalar L, Attin S. Improving Hear rate variability in step apnea patients: differences in treatment with auto-titrating positive airway pressure (APAP) versus conventional CPAP. Lung. 2010;188(4):315-20.</li> <li>43. Patruno V, Tobaldini E, Bianchi AM, Mendez MO, Coletti O, Costantino G, et al. Acute effects of autoadjusting and fixed continuous positive airway pressure treatments on cardioespiratory coupling in obsee patients with obstructive sleep apnea. European journal of internal medicine. 2014;25(2):164-8.</li> <li>44. Bamner JW, Taylor JA. Automated quantification of sympathetic beat-by beat activity, independent of signal quality. Journal of applied physiology. 2001;91(3):1199-206.</li> <li>51. Tan CO, Tamisier R, Hammer JW, Taylor JA. Characterizing sympathetic neurovascular transduction in humans. PloS one. 2013;8(1):e33769.</li> <li>52. Williams B, Mancia G, Spiering W, Agabiti Rosel E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension. The Task Force for the management of arterial hypertension. The Task Force for the management of arterial hypertension. The Task Force for the management of arterial hypertension. The Task Force for the management of arterial hypertension. 2018;35(10):1953-2041.</li> <li>53. Mancia G, De Backer G, Dominiczak A, CiKwas R, Fagard R, Germano G, et al. 2007 Guidelines for the truopean Society of Thypertension. 2007;25(6):1105-87.</li> <li>54. Berry RB, Brooks R, Gamaido C, Harding SM, Lloyd RM, Quan SF, et al. AASM Scoring Manual Updets for 2017 (Version 2.4). Journal of functional sleep medicine. 2015;12(5):105-01.</li> <li>54. Berry RB, Brooks R, Garmado C, Harding SM, Lloyd RM, Quan SF, et al. AASM Scoring Manual Updets for 2017 (Version 2.4). Journal of Sciep feedical Sciep reference. 2015;12(1):49-56.</li> <li>55. Sitte LL, Uroso DD, Yadollah J, Ayan CM, Bradlet TD. Night-to-night v</li></ul>	10	15	nasal CPAP therapy for obstructive sleep apnoea. Thorax. 2006;61(3):226-31.
1       patients: differences in treatment with auto-titrating positive airway pressure (APAP) versus conventional         0       19       48. Patruno V, Tobaldini F, Bianchi AM, Mendez MO, Coletti O, Costantino G, et al. Acute effects of autodiguisting and fixed continuous positive airway pressure treatments on cardiorspictary coupling in obese patients with obstructive sleep apnea. European journal of internal medicine. 2014;25(2):164-8.         21       49. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;24(4):540-5.         22       50. Hammer JW, Taylor JA. Automated quantification of sympathetic beat-by-beat activity, independent of signal quality. Journal of applied physiology. 2001;31(3):1199-20.         23       51. Tan CO, Tamiser R, Hammer JW, Taylor JA. Characterizing sympathetic neurovascular transduction in humans. PloS one. 2013;8(1):e53769.         23       52. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Phypertension. The Task Force for the Management of Arterial Hypertension: Data Sk Drice for the Management of Arterial Hypertension: Data Sk Force for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension: The Task Force for the Management	1/	16	47. Karasulu L, Epozturk PO, Sokucu SN, Dalar L, Altin S. Improving Heart rate variability in sleep apnea
<ul> <li>CMAP. Lung. 2010;1288(4):315-20.</li> <li>CMAP. Lung. 2010;1288(4):315-20.</li> <li>Saturoa V, Tobaldini F, Bianchi AM, Mendez MO, Coletti O, Costantino G, et al. Acute effects of autoadjusting and fixed continuous positive airway pressure treatments on cardiorespiratory coupling in obese patients with obstructive sleep anea. European journal of internal medicine. 2014;25(2):164-8.</li> <li>Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep.</li> <li>Jian CO, Tamisier R, Hammer JW, Taylor JA. Automated quantification of sympathetic beat-by-beat activity, independent of signal quality. Journal of applied physiology. 2001;91(3):1199-206.</li> <li>Tan CO, Tamisier R, Hammer JW, Taylor JA. Characterizing sympathetic neurovascular transduction in humans. PloS one. 2013;8(1):e53769.</li> <li>Su. Williams B, Mancia G, Splering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension.</li> <li>Tam CO, Tamisier R, Hammer JM, Taylor JA. Chava R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension. of the European Society of Hypertension of the European Society of Hypertension. 2012;6(1):105-87.</li> <li>Su. Mancia G, De Backer G, Dominiczak A, Citkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension of the European Society of Ardiology (ESC). Journal of hypertension. 2012;5(1):105-87.</li> <li>Su. Berry RB, Brooks R, Gamaido C, Harding SM, Lloyd RM, Quan SF, et al. ASM Scoring Manual Updates for 2017 (Version 2.4). Journal of clinical sleep medicine: JCSM : official publication of the American Academy of Sleep Medicine. 2015;11(2):149-56.</li> <li>Su White LH, Lyons OD, Yadolilahi A, Ryan CM, Bradley TD. Night-to-night varability in obst</li></ul>	18	1/	patients: differences in treatment with auto-titrating positive airway pressure (APAP) versus conventional
19       48. Patruno V, foodionit, Bianchi AM, Mendez MO, Colstati O, Costantino G, et al. Acute effects of         21       autoadjusting and fixed continuous positive airway pressure treatments on cardiorespiratory coupling in obese         22       patients with obstructive sleep apnea. European journal of internal medicine. 2014;25(2):164-8.         23       49. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep.         24       1991;14(6):540-5.         25       50. Hammer JW, Taylor JA. Automated quantification of sympathetic beat-by-beat activity, independent of         26       51. Tan CO, Tamisler R, Hammer JW, Taylor JA. Characterizing sympathetic neurovascular transduction in         27       Williams B, Mancia G, Spiering W, Agabiti Rosel F, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines         28       52. Williams B, Mancia G, Spiering W, Agabiti Rosel F, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines of         29       for the management of arterial hypertension: The Task Force for the management of arterial hypertension. 2013;32(10):193-2041.         31       53. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the         31       53. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2047 Guidelines for the         32       For 2017 (Version 2.4). Journal of the European Society of Cardiology (ESC). Journal of         34       Management of Arterial Hypertension: The Task Force for the	19	18	CPAP. Lung. 2010;188(4):315-20.
20       autoadjusting and heed continuous positive airway pressure treatments on cardiorespiratory coupling in obese         21       49       Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep.         22       49       Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep.         23       50.       Hamner JW, Taylor JA. Automated quantification of sympathetic beat-by-beat activity, independent of signal quality. Journal of applied physiology. 2001;91(3):1199-206.         24       51.       Tan CO. Tamisler R, Hamner JW, Taylor JA. Characterizing sympathetic neurovascular transduction in humans. PloS one. 2013;8(1):e53769.         25       Williams B, Mancia G, Splering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Cardiology and the European Society of Cardiology and the European Society of Itypertension. Journal of hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology (ESC). Journal of the European Society of Cardiology (ESC). Journal of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of the Septension. 2007; 25(6):1105-87.         37       54.       Berry RB, Brooks R, Gamaldo C, Harding SM, Lloyd RM, Quan SF, et al. ASM Scoring Manual Updates for 2017 (Version 2.4). Journal of tinical sleep medicine: JCSM : official publication of the American Academy of Sleep Medicine. 2017;13(5):665-6.         38       Bittencourt LR, Sucheck DT, Tufik S, Peres C, Togeiro SM,	20	19	48. Patruno V, Tobaldini E, Bianchi AM, Mendez MO, Coletti O, Costantino G, et al. Acute effects of
<ul> <li>21 patients with obstructive silep aprice, European journal or internal medicine 2014;25(2):164-8.</li> <li>49. Johns MW. A new method for measuring daytime sileepiness: the Epworth sileepiness cale. Sleep.</li> <li>31. Johns MW. A new method for measuring daytime sileepiness: the Epworth sileepiness cale. Sleep.</li> <li>32. Manner JW, Taylor JA. Automated quantification of sympathetic beat-by-beat activity, independent of signal quality. Journal of applied physiology. 2001;91(3):1199-206.</li> <li>32. Milliams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESZ/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. The Task Force for the Management of Arterial Hypertension. 2018;36(1):e535-03.</li> <li>33. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension. 2018;36(1):e535-03.</li> <li>34. Berry RB, Brooks R, Gamaldo C, Harding SM, Lloyd RM, Quan SF, et al. ASM Scoring Manual Updates for Z017 (Version 2.4). Journal of clinical sleep medicine: JCSM : official publication of the American Academy of Sleep Medicine. 2017;31(5):665-6.</li> <li>35. Minte LH, Lyoos DO, Yadollahi A, Ryan CM, Bradley TD. Night-to-night variability in obstructive sleep apnee severity: relationship to overnight rostral fluid shift. Journal of functian sleep medicine: JCSM : official publication of the American Academy of Sleep Medicine. 2017;13(5):665-6.</li> <li>36. Bittencourt LR, Sucheck D, Juris S, Peres C, Togeiro SM, Bagnato MC, et al. The variability of the apnee-hypoponea index. Journal of sleep Research. 2001;10(3):245-51.</li> <li>37. Stradling IR, Barabour C, Priston DJ, Davies RJ. Automatic nasal continuous posi</li></ul>	21	20	autoadjusting and fixed continuous positive airway pressure treatments on cardiorespiratory coupling in obese
<ul> <li>49. Johns WW. A new method for measuring daytime steepness: the Epworth steepness scale. Steep.</li> <li>1991;14(6):540-5.</li> <li>50. Hamner JW, Taylor JA. Automated quantification of sympathetic beat-by-beat activity, independent of signal quality. Journal of applied physiology. 2001;91(3):1199-206.</li> <li>51. Tan CO, Tamisler R, Hamner JW, Taylor JA. Characterizing sympathetic neurovascular transduction in humans. PloS one. 2013;8(1):e53769.</li> <li>52. Williams B, Mancia G, Spiering W. Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Cardiology and the European Society of Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension: 2007;55(6):1105-87.</li> <li>54. Berry RB, Brooks R, Gamaldo C, Harding SM, Lloyd RM, Quan SF, et al. AASM Scoring Manual Updates for 2017 (Version 2.4). Journal of clinical sleep medicine: JCSM : official publication of the American Academy of Sleep Medicine. 2017;13(5):665-6.</li> <li>55. White LH, Lyons OD, Yadollahi A, Ryan CM, Bradley TD. Night-to-night variability in obstructive sleep apnea severity: relationship to overnight rostral fluid shift. Journal of linical sleep medicine: JCSM : official publication of the American Academy of Sleep Medicine. 2017;13(5):665-6.</li> <li>56. Bittencourt LR, Suchecki D, Tufik S, Peres C, Toggiro SM, Bagnato MC, et al. The variability of the apneea-hypopnoea index. Journal of sleep research. 2001;10(3):245-51.</li> <li>57. Stradling JR, Barbour C, Pitson JD, Davies RJ. Automati</li></ul>	22	21	patients with obstructive sleep apnea. European journal of internal medicine. 2014;25(2):164-8.
<ul> <li>1991,14(0):3405.</li> <li>Hamner JW, Taylor JA. Automated quantification of sympathetic beat-by-beat activity, independent of signal quality. Journal of applied physiology. 2001;91(3):1199-206.</li> <li>Tan CO, Tamisier R, Hamner JW, Taylor JA. Characterizing sympathetic neurovascular transduction in humans. PloS one. 2013;8(1):e53769.</li> <li>Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension. 2013;8(10):1953-2041.</li> <li>Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial hypertension: The Task Force for the Management of Arterial hypertension. 2013;8(10):1953-2041.</li> <li>Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial hypertension: The Task Force for the Management of Arterial hypertension. 2013;8(10):1953-2041.</li> <li>Mancia G, De Backer G, Boroiks R, Gamaldo C, Harding SM, Lloyd RM, Quan SF, et al. AASM Scoring Manual Updates for 2017 (Version 2.4). Journal of clinical sleep medicine: JCSM : official publication of the American Academy of Sleep Medicine. 2017;13(5):665-6.</li> <li>Sh. White LH, Lyons OD, Yadollahi A, Ryan CM, Bradley TD. Night-to-night variability in obstructive sleep apnea severity: relationship to overnight rostral fluid shift. Journal of clinical sleep medicine: JCSM : official publication of the American Academy of Sleep Medicine. 2017;13(5):665-6.</li> <li>Sh. Bittencourt LR, Suchecki D, Tufik S, Peres C, Togeiro SM, Bagnato MC, et al. The variability of the apnoea-hypoponea index. Journal of sleep research. 2001;10(3):245-51.</li> <li>Sh. Corral J, Sanchez-Quiroga MA, Carmona-Bernal C, Sanchez-Armegol A, de la Torre AS, Duran-Cantolla J, et al. Conventional Polysommography Is Not Necessary for the Management of Most Patients with Su</li></ul>	23	22	49. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep.
<ul> <li>Su. A manner IW, Taylor JA. Automated quartication of Sympathetic basic-by-beat activity, independent of signal quality. Journal of applied physiology. 2001;91(3):1199-266.</li> <li>Su. Milliams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension. The Task Force for the management of arterial hypertension. The Task Force for the management of arterial hypertension. 2018;36(10):1953-2041.</li> <li>Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension. (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension. 2013;36(10):1953-2041.</li> <li>Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension. (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension. 2007;25(6):1105-87.</li> <li>Sa. Merry RB, Brooks R, Gamaldo C, Harding SM, Ludyd RM, Quan SF, et al. AASM Scoring Manual Updates for 2017 (Version 2.4). Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2017;13(5):665-6.</li> <li>S. White LH, Lyons OD, Yadollahi A, Ryan CM, Bradley TD. Night-to-night variability in obstructive sleep apea severity: relationship to overnight rostral fluid shift. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2015;11(2):149-56.</li> <li>S. Bittencourt LR, Suchecki D, Tuffi S, Peres C, Togeiro SM, Bagnato MC, et al. The variability of the apnoea-hypopnoea index. Journal of sleep reserch. 2001;10(3):245-51.</li> <li>S. Corral J, Sanchez-Quiroga MA, Carmona-Bernal C, Sanchez-Armengol A, de la Torre AS, Duran-Cantolla J, et al. Conventional Polysomnography Is Not Necessary for</li></ul>	24	23	1991;14(b):540-5.
<ul> <li>Seltia (Jointy Jointa) (Jointa) applied physiology. 2001; 91(3):1199-200.</li> <li>Salta (Jointy Jointa) (Jointa) (Jointa</li></ul>	25	24	signal quality, lawral of applied physiology, 2001,01/2),1100,206
<ul> <li>Si. Ten CG, rained K, ramine K, ramo JA, Chardelizing Sympatited redivascular dansbuction in humans. PloS one 2013;8(1):e53769.</li> <li>Si. Williams B, Mancia G, Spiering W, Agabiti Rosei F, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension: The Task Force for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension (ESH) and the European Society of Cardiology and the European Society of Arterial Hypertension: 0(19) and the European Society of Cardiology (ESC). Journal of hypertension. 2007;25(6):1105-87.</li> <li>Sa Berry RB, Brooks R, Gamaldo C, Harding SM, Lloyd RM, Quan SF, et al. AASM Scoring Manual Updates for 2017 (Version 2.4). Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2017;13(5):665-6.</li> <li>S. White LH, Lyons OD, Yadollah A, Ryan CM, Bradley TD. Night-to-night variability in obstructive sleep apneae severity: relationship to overnight rostral fluid shift. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2017;13(5):665-6.</li> <li>S. White LH, Lyons OD, Yadollah A, Ryan CM, Bradley TD. Night-to-night variability in obstructive sleep apneae severity: relationship to overnight rostral fluid shift. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2015;11(2):149-56.</li> <li>S. Suthet D, Sucheck D, D, Davies RJ. Automatic nasal continuous positive airway pressure titration in the laboratory: patient outcomes. Thorax. 1997;52(1):72-5.</li> <li>S. Corral J, Sanchez-Quiroga MA, Carmona-Bernal C, Sanchez-Armengol A, de la Torre AS, Duran-Cantolla J, et al. Conventiona</li></ul>	26	25	Signal quality. Journal of applied physiology. 2001,91(3).1199-200.
<ul> <li>Multians P. Moother. 2005 (1):105-00.</li> <li>Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension.</li> <li>Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension. 2018;36(10):1953-2041.</li> <li>Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of hypertension. 2007;25(6):1105-87.</li> <li>Berry RB, Brooks R, Gamaldo C, Harding SM, Lloyd RM, Quan SF, et al. AASM Scoring Manual Updates for 2017 (Version 2.4). Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2017;13(5):665-6.</li> <li>White LH, Lyons OD, Yadollahi A, Ryan CM, Bradley TD. Night-to-night variability in obstructive sleep apnea severity: relationship to overnight rostral fluid shift. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2015;11(2):149-56.</li> <li>Bittencourt LR, Suchecki D, Tufik S, Peres C, Togeiro SM, Bagnato MC, et al. The variability of the apnea-hypoponea index. Journal of sleep research. 2001;10(3):245-51.</li> <li>Stardling JR, Barbour C, Pitson DJ, Davies RJ. Automatic nasal continuous positive airway pressure titration in the laboratory: patient outcomes. Thorax. 1997;52(1):72-5.</li> <li>Stardling JR, Barbour C, Pitson DJ, Davies RJ. Automatic nasal continuous positive airway pressure do continuous positive airway pressure machines for adults with obstructive sleep apneea. Cochrane Database Syst Rev. 2009(2):CD007736.</li></ul>	27	20	bumphe DioS one 2012:0/1):eE2760
<ul> <li>S2. Winking C, Spering W, Again Nosel C, Atzin J, Bulniel M, et al. 2018 (2017) Outpetitions</li> <li>S3. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension. 2018;36(10):1953-2041.</li> <li>S3. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension. 2018;36(10):1953-2041.</li> <li>S3. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension. 2018;36(10):1953-2041.</li> <li>S4. Berry RB, Brooks R, Gamaldo C, Harding SM, Lloyd RM, Quan SF, et al. AASM Scoring Manual Updates for 2017 (Version 2.4). Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2017;13(5):665-6.</li> <li>S5. White LH, Lyons OD, Yadollahi A, Ryan CM, Bradley TD. Night-to-night variability in obstructive sleep apnea severity: relationship to overnight rostral fluid shift. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2015;11(2):149-56.</li> <li>S6. Bittencourt LR, Suchecki D, Tufik S, Peres C, Togeiro SM, Bagnato MC, et al. The variability of the apnoea-hypoponea index. Journal of sleep research. 2001;10(3):245-51.</li> <li>S7. Stradling JR, Barbour C, Pitson DJ, Davies RJ. Automatic nasal continuous positive airway pressure titration in the laboratory: patient outcomes. Thorax. 1997;52(1):72-5.</li> <li>S8. Corral J, Sanchez-Quiroga MA, Carmona-Bernal C, Sanchez-Armengol A, de la Torre AS, Duran-Cantolla J, et al. Conventional Polysomorgraph is Not Necessary for the Management of Most Patients with Suspected Obstructive Sleep Apnea. Noninferiority, Randomized Controlled Trial. American journal of respiratory and critical are medicine. 2017;195(9):1181-90.</li> <li>S9. Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural</li></ul>	28	27	Nullians, Plos olie, 2015,6(1),855705.
<ul> <li>bit die unangement of arteriaar lypertension. The Task Force for the management of arteriaal hypertension of the European Society of Cardiology and the European Society of Hypertension. The Task Force for the management of arterial hypertension. 2018;36(10):1953-2041.</li> <li>Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension. 2007;25(6):1105-87.</li> <li>Mancia C, De Backer G, Bando C, Harding SM, Lloyd RM, Quan SF, et al. AASM Scoring Manual Updates for 2017 (Version 2.4). Journal of clinical sleep medicine: ICSM : official publication of the American Academy of Sleep Medicine. 2017;13(5):665-6.</li> <li>Si. White LH, Lyons OD, Yadollahi A, Ryan CM, Bradley TD. Night-to-night variability in obstructive sleep apnea severity: relationship to overnight rostral fluid shift. Journal of clinical sleep medicine: JCSM : official publication of the American Academy of Sleep Medicine. 2015;11(2):149-56.</li> <li>Si. Bittencourt LR, Suchecki D, Tufik S, Peres C, Togeiro SM, Bagnato MC, et al. The variability of the apnoea-hypopnoea index. Journal of Joures RJ. Automatic nasal continuous positive airway pressure titration in the laboratory: patient outcomes. Thorax. 1997;52(1):72-5.</li> <li>St. Corral J, Sanchez-Quiroga MA, Carmona-Bernal C, Sanchez-Armengol A, de la Torre AS, Duran-Cantolla J, et al. Conventional Polysomnography Is Not Necessary for the Management of Most Patients with Suspected Obstructive Sleep Apnea. Noninferiority, Randomized Controlled Trial. American journal of respiratory and critical are medicine. 2017;115(1):181-90.</li> <li>Si. Smith I, Nadig V, Lasserson JJ. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines for adults with obstructive sleep apneea. Cochrane Database Syst Rev. 2009(2):CD00736.</li> <li>Vallbo AB, Hagbarth KE. Impulses record</li></ul>	29	20	for the management of arterial hypertension. The Task Force for the management of arterial hypertension of
111	30	30	the European Society of Cardiology and the European Society of Hypertension: The Task Force for the
<ul> <li>Humangenetical of uteration type and the second standard of the damagement of Arterial Hypertension. 2018;36(10):1953-2041.</li> <li>Saman Carl A, Carl A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of hypertension. 2007;25(6):1105-87.</li> <li>Saman C, Carl A, Berry RB, Brooks R, Gamaldo C, Harding SM, Lloyd RM, Quan SF, et al. AASM Scoring Manual Updates for 2017 (Version 2.4). Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2017;13(5):665-6.</li> <li>White LH, Lyons OD, Yadollahi A, Ryan CM, Bradley TD. Night-to-night variability in obstructive sleep apnea severity: relationship to overnight rostral fluid shift. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2017;13(5):665-6.</li> <li>Bittencourt LR, Suchecki D, Tufik S, Peres C, Togeiro SM, Bagnato MC, et al. The variability of the apnea-avypopnea index. Journal of sleep research. 2001;10(3):245-51.</li> <li>Bittencourt LR, Suchecki D, Tufik S, Peres C, Togeiro SM, Bagnato MC, et al. The variability of the apneea-hypopnea index. Journal of sleep research. 2001;10(3):245-51.</li> <li>Stradling JR, Barbour C, Pitson DJ, Davies RJ. Automatic nasal continuous positive airway pressure titration in the laboratory: patient outcomes. Thorax. 1997;52(1):72-5.</li> <li>Strading JR, Barbour C, Pitson DJ, Davies RJ. Automatic nasal continuous positive airway pressure double slowed or spismatory and controlled Trial. American journal of respiratory and critical care medicine. 2017;196(9):1181-90.</li> <li>Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines for adults with obstructive sleep apneea. Cochrane Database Syst Rev. 2009(2):CD007736.</li> <li>Nalabarth KE. Impulses recorded with mi</li></ul>	31	30	management of arterial hypertension of the European Society of Cardiology and the European Society of
<ul> <li>S. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of hypertension. 2007;25(5):1105-87.</li> <li>S4. Berry RB, Brooks R, Gamaldo C, Harding SM, Lloyd RM, Quan SF, et al. AASM Scoring Manual Updates for 2017 (Version 2.4). Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2017;13(5):665-6.</li> <li>S. White LH, Lyons OD, Yadollahi A, Ryan CM, Bradley TD. Night-to-night variability in obstructive sleep apnea severity: relationship to overnight rostral fluid shift. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 5(5):11(2):149-56.</li> <li>S6. Bittencourt LR, Suchecki D, Tufik S, Peres C, Togeiro SM, Bagnato MC, et al. The variability of the apneea-hypopnoea index. Journal of sleep research. 2001;10(3):245-51.</li> <li>S7. Stradling JR, Barbour C, Pitson DJ, Davies RJ. Automatic nasal continuous positive airway pressure titration in the laboratory: patient outcomes. Thorax. 1997;52(1):72-5.</li> <li>S8. Corral J, Sanchez-Quiroga MA, Carmona-Bernal C, Sanchez-Armengol A, de la Torre AS, Duran-Cantolla J, et al. Conventional Polysomnography Is Not Necessary for the Management of Most Patients with Suspected Obstructive Sleep Apnea. Noninferiority, Randomized Controlled Trial. American journal of respiratory and critical care medicine. 2017;13(6):1181-90.</li> <li>S9. Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines for adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2009(2):CD007736.</li> <li>S0. Vallbo AB, Hagbarth KE. Impulses recorded with micro-electrodes in human muscle nerves during stimula</li></ul>	32	32	Hypertension Journal of hypertension 2018:36(10):1953-2041
<ul> <li>Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of hypertension. 2007;25(6):1105-87.</li> <li>S4. Berry RB, Brooks R, Gamaldo C, Harding SM, Lloyd RM, Quan SF, et al. AASM Scoring Manual Updates for 2017 (Version 2.4). Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2017;13(5):665-6.</li> <li>Wo 55. White LH, Lyons OD, Yadollahi A, Ryan CM, Bradley TD. Night-to-night variability in obstructive sleep apnea severity: relationship to overnight rostral fluid shift. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2015;11(2):149-56.</li> <li>Bittencourt LR, Suchecki D, Tufik S, Peres C, Togeiro SM, Bagnato MC, et al. The variability of the apneea-hypopnoea index. Journal of sleep research. 2001;10(3):245-51.</li> <li>S7. Stradling JR, Barbour C, Pitson JD, Davies RJ. Automatic nasal continuous positive airway pressure titration in the laboratory: patient outcomes. Thorax. 1997;52(1):72-5.</li> <li>S8. Corral J, Sanchez-Quiroga MA, Carmona-Bernal C, Sanchez-Armengol A, de la Torre AS, Duran-Cantolla J, et al. Conventional Polysomnograph Is Not Necessary for the Management of Most Patients with Suspected Obstructive Sleep Apnea. Noninferiority, Randomized Controlled Trial. American journal of respiratory and critical care medicine. 2017;196(9):1181-90.</li> <li>S9. Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines for adults with obstructive sleep apneae. Cochrane Database Syst Rev. 2009(2):CD007736.</li> <li>Vallbo AB, Hagbarth KE. Impulses recorded with micro-electrodes in human muscle nerves during stimulation of mechanoreceptors and voluntary contractions. Electroencephalogr Clin Neurophysiol. 1967;23(4):392.&lt;</li></ul>	33	33	53. Mancia G. De Backer G. Dominiczak A. Cifkova R. Fagard R. Germano G. et al. 2007 Guidelines for the
<ul> <li>European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of hypertension. 2007;25(6):1105-87.</li> <li>S4. Berry RB, Brooks R, Gamaldo C, Harding SM, Lloyd RM, Quan SF, et al. AASM Scoring Manual Updates for 2017 (Version 2.4). Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2017;13(5):665-6.</li> <li>40. 40. 55. White LH, Lyons OD, Yadollahi A, Ryan CM, Bradley TD. Night-to-night variability in obstructive sleep apnea severity: relationship to overnight rostral fluid shift. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2015;11(2):149-56.</li> <li>43. 56. Bittencourt LR, Suchecki D, Tufik S, Peres C, Togeiro SM, Bagnato MC, et al. The variability of the apnea-hypopnoe index. Journal of sleep research. 2001;11(3):245-51.</li> <li>45. 57. Stradling JR, Barbour C, Pitson DJ, Davies RJ. Automatic nasal continuous positive airway pressure titration in the laboratory: patient outcomes. Thorax. 1997;52(1):72-5.</li> <li>47. 58. Corral J, Sanchez-Quiroga MA, Carmona-Bernal C, Sanchez-Armengol A, de la Torre AS, Duran-Cantolla J, et al. Conventional Polysomnography Is Not Necessary for the Management of Most Patients with Suspected Obstructive Sleep Apnea. Noninferiority, Randomized Controlled Trial. American journal of respiratory and critical care medicine. 2017;196(9):1181-90.</li> <li>59. Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines for adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2009(2):CD007736.</li> <li>60. Vallbo AB, Hagbarth KE. Impulses recorded with micro-electrodes in human muscle nerves during stimulation of mechanoreceptors and voluntary contractions. Electroencephalogr Clin Neurophysiol. 1967;23(4):392.</li> </ul>	34	34	Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the
<ul> <li>hypertension. 2007;25(6):1105-87.</li> <li>54. Berry RB, Brooks R, Gamaldo C, Harding SM, Lloyd RM, Quan SF, et al. AASM Scoring Manual Updates</li> <li>for 2017 (Version 2.4). Journal of clinical sleep medicine : JCSM : official publication of the American Academy</li> <li>of Sleep Medicine. 2017;13(5):665-6.</li> <li>40</li> <li>55. White LH, Lyons OD, Yadollahi A, Ryan CM, Bradley TD. Night-to-night variability in obstructive sleep</li> <li>apnea severity: relationship to overnight rostral fluid shift. Journal of clinical sleep medicine : JCSM : official</li> <li>publication of the American Academy of Sleep Medicine. 2015;11(2):149-56.</li> <li>56. Bittencourt LR, Suchecki D, Tufik S, Peres C, Togeiro SM, Bagnato MC, et al. The variability of the</li> <li>apnoea-hypopnoea index. Journal of sleep research. 2001;10(3):245-51.</li> <li>57. Stradling JR, Barbour C, Pitson DJ, Davies RJ. Automatic nasal continuous positive airway pressure</li> <li>titration in the laboratory: patient outcomes. Thorax. 1997;52(1):72-5.</li> <li>58. Corral J, Sanchez-Quiroga MA, Carmona-Bernal C, Sanchez-Armengol A, de la Torre AS, Duran-Cantolla</li> <li>J, et al. Conventional Polysomnography Is Not Necessary for the Management of Most Patients with Suspected</li> <li>Obstructive Sleep Apnea. Noninferiority, Randomized Controlled Trial. American journal of respiratory and</li> <li>critical care medicine. 2017;196(9):1181-90.</li> <li>59. Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to improve usage</li> <li>of continuous positive airway pressure machines for adults with obstructive sleep apnoea. Cochrane Database</li> <li>Syst Rev. 2009(2):CD007736.</li> <li>60. Vallbo AB, Hagbarth KE. Impulses recorded with micro-electrodes in human muscle nerves during</li> <li>stimulation of mechanoreceptors and voluntary contractions. Electroencephalogr Clin Neurophysiol.</li> <li>1967;23(4):392.</li> </ul>	35	35	European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of
<ul> <li>37 37 54. Berry RB, Brooks R, Gamaldo C, Harding SM, Lloyd RM, Quan SF, et al. AASM Scoring Manual Updates</li> <li>38 38 for 2017 (Version 2.4). Journal of clinical sleep medicine : JCSM : official publication of the American Academy</li> <li>39 of Sleep Medicine. 2017;13(5):665-6.</li> <li>40 40 55. White LH, Lyons OD, Yadollahi A, Ryan CM, Bradley TD. Night-to-night variability in obstructive sleep</li> <li>41 apnea severity: relationship to overnight rostral fluid shift. Journal of clinical sleep medicine : JCSM : official</li> <li>42 42 publication of the American Academy of Sleep Medicine. 2015;11(2):149-56.</li> <li>43 56. Bittencourt LR, Suchecki D, Tufik S, Peres C, Togeiro SM, Bagnato MC, et al. The variability of the</li> <li>44 apnoea-hypopnoea index. Journal of sleep research. 2001;10(3):245-51.</li> <li>45 57. Stradling JR, Barbour C, Pitson DJ, Davies RJ. Automatic nasal continuous positive airway pressure</li> <li>46 titration in the laboratory: patient outcomes. Thorax. 1997;52(1):72-5.</li> <li>47 58. Corral J, Sanchez-Quiroga MA, Carmona-Bernal C, Sanchez-Armengol A, de la Torre AS, Duran-Cantolla</li> <li>48 49 J, et al. Conventional Polysomnography Is Not Necessary for the Management of Most Patients with Suspected</li> <li>49 Obstructive Sleep Apnea. Noninferiority, Randomized Controlled Trial. American journal of respiratory and</li> <li>51 59. Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to improve usage</li> <li>52 of continuous positive airway pressure machines for adults with obstructive sleep apnoea. Cochrane Database</li> <li>53 Syst Rev. 2009(2):CD007736.</li> <li>54 60. Vallbo AB, Hagbarth KE. Impulses recorded with micro-electrodes in human muscle nerves during</li> <li>55 stimulation of mechanoreceptors and voluntary contractions. Electroencephalogr Clin Neurophysiol.</li> <li>56 1967;23(4):392.</li> </ul>	36	36	hypertension. 2007;25(6):1105-87.
3838for 2017 (Version 2.4). Journal of clinical sleep medicine : JCSM : official publication of the American Academy3939of Sleep Medicine. 2017;13(5):665-6.404055. White LH, Lyons OD, Yadollahi A, Ryan CM, Bradley TD. Night-to-night variability in obstructive sleep41apnea severity: relationship to overnight rostral fluid shift. Journal of clinical sleep medicine : JCSM : official42publication of the American Academy of Sleep Medicine. 2015;11(2):149-56.434356. Bittencourt LR, Suchecki D, Tufik S, Peres C, Togeiro SM, Bagnato MC, et al. The variability of the4444apnoea-hypopnoea index. Journal of sleep research. 2001;10(3):245-51.454557. Stradling JR, Barbour C, Pitson DJ, Davies RJ. Automatic nasal continuous positive airway pressure4646titration in the laboratory: patient outcomes. Thorax. 1997;52(1):72-5.4748J, et al. Conventional Polysomnography Is Not Necessary for the Management of Most Patients with Suspected4949Obstructive Sleep Apnea. Noninferiority, Randomized Controlled Trial. American journal of respiratory and critical care medicine. 2017;196(9):1181-90.5159. Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines for adults with obstructive sleep apneea. Cochrane Database Syst Rev. 2009(2):CD007736.535460. Vallbo AB, Hagbarth KE. Impulses recorded with micro-electrodes in human muscle nerves during stimulation of mechanoreceptors and voluntary contractions. Electroencephalogr Clin Neurophysiol. 1967;23(4):392.561967;23(4):392. </td <td>37</td> <td>37</td> <td>54. Berry RB, Brooks R, Gamaldo C, Harding SM, Lloyd RM, Quan SF, et al. AASM Scoring Manual Updates</td>	37	37	54. Berry RB, Brooks R, Gamaldo C, Harding SM, Lloyd RM, Quan SF, et al. AASM Scoring Manual Updates
3939of Sleep Medicine. 2017;13(5):665-6.404055. White LH, Lyons OD, Yadollahi A, Ryan CM, Bradley TD. Night-to-night variability in obstructive sleep4141apnea severity: relationship to overnight rostral fluid shift. Journal of clinical sleep medicine : JCSM : official4242publication of the American Academy of Sleep Medicine. 2015;11(2):149-56.434356. Bittencourt LR, Suchecki D, Tufik S, Peres C, Togeiro SM, Bagnato MC, et al. The variability of the4444apnoea-hypopnoea index. Journal of sleep research. 2001;10(3):245-51.4557. Stradling JR, Barbour C, Pitson DJ, Davies RJ. Automatic nasal continuous positive airway pressure46titration in the laboratory: patient outcomes. Thorax. 1997;52(1):72-5.474748J, et al. Conventional Polysomnography Is Not Necessary for the Management of Most Patients with Suspected49Obstructive Sleep Apnea. Noninferiority, Randomized Controlled Trial. American journal of respiratory and critical care medicine. 2017;196(9):1181-90.5159. Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines for adults with obstructive sleep apneea. Cochrane Database Syst Rev. 2009(2):CD007736.5556561967;23(4):392.575657For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	38	38	for 2017 (Version 2.4). Journal of clinical sleep medicine : JCSM : official publication of the American Academy
404055.White LH, Lyons OD, Yadollahi A, Ryan CM, Bradley TD. Night-to-night variability in obstructive sleep4141apnea severity: relationship to overnight rostral fluid shift. Journal of clinical sleep medicine : JCSM : official4242publication of the American Academy of Sleep Medicine. 2015;11(2):149-56.434356.Bittencourt LR, Suchecki D, Tufik S, Peres C, Togeiro SM, Bagnato MC, et al. The variability of the4444apnoea-hypopnea index. Journal of sleep research. 2001;10(3):245-51.454557.Stradling JR, Barbour C, Pitson DJ, Davies RJ. Automatic nasal continuous positive airway pressure4646titration in the laboratory: patient outcomes. Thorax. 1997;52(1):72-5.474758.Corral J, Sanchez-Quiroga MA, Carmona-Bernal C, Sanchez-Armengol A, de la Torre AS, Duran-Cantolla4848J, et al. Conventional Polysomnography Is Not Necessary for the Management of Most Patients with Suspected4949Obstructive Sleep Apnea. Noninferiority, Randomized Controlled Trial. American journal of respiratory and critical care medicine. 2017;196(9):1181-90.5159.Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines for adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2009(2):CD007736.535460.Vallbo AB, Hagbarth KE. Impulses recorded with micro-electrodes in human muscle nerves during stimulation of mechanoreceptors and voluntary contractions. Electroencephalogr Clin Neurophysiol. 1967;23(4):392.561967;23(4):392.5	39	39	of Sleep Medicine. 2017;13(5):665-6.
4141apnea severity: relationship to overnight rostral fluid shift. Journal of clinical sleep medicine : JCSM : official4242publication of the American Academy of Sleep Medicine. 2015;11(2):149-56.434356. Bittencourt LR, Suchecki D, Tufik S, Peres C, Togeiro SM, Bagnato MC, et al. The variability of the4444apneea-hypopnoea index. Journal of sleep research. 2001;10(3):245-51.454557. Stradling JR, Barbour C, Pitson DJ, Davies RJ. Automatic nasal continuous positive airway pressure4646titration in the laboratory: patient outcomes. Thorax. 1997;52(1):72-5.474758. Corral J, Sanchez-Quiroga MA, Carmona-Bernal C, Sanchez-Armengol A, de la Torre AS, Duran-Cantolla4848J, et al. Conventional Polysomnography Is Not Necessary for the Management of Most Patients with Suspected4949Obstructive Sleep Apnea. Noninferiority, Randomized Controlled Trial. American journal of respiratory and critical care medicine. 2017;196(9):1181-90.515159. Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines for adults with obstructive sleep apneea. Cochrane Database Syst Rev. 2009(2):CD007736.535460. Vallbo AB, Hagbarth KE. Impulses recorded with micro-electrodes in human muscle nerves during stimulation of mechanoreceptors and voluntary contractions. Electroencephalogr Clin Neurophysiol. 1967;23(4):392.54561967;23(4):392.565656575758Corp peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml <td>40</td> <td>40</td> <td>55. White LH, Lyons OD, Yadollahi A, Ryan CM, Bradley TD. Night-to-night variability in obstructive sleep</td>	40	40	55. White LH, Lyons OD, Yadollahi A, Ryan CM, Bradley TD. Night-to-night variability in obstructive sleep
4242publication of the American Academy of Sleep Medicine. 2015;11(2):149-56.434356.Bittencourt LR, Suchecki D, Tufik S, Peres C, Togeiro SM, Bagnato MC, et al. The variability of the4444apnoea-hypopnoea index. Journal of sleep research. 2001;10(3):245-51.454557.Stradling JR, Barbour C, Pitson DJ, Davies RJ. Automatic nasal continuous positive airway pressure4646titration in the laboratory: patient outcomes. Thorax. 1997;52(1):72-5.474758.Corral J, Sanchez-Quiroga MA, Carmona-Bernal C, Sanchez-Armengol A, de la Torre AS, Duran-Cantolla4848J, et al. Conventional Polysomnography Is Not Necessary for the Management of Most Patients with Suspected4949Obstructive Sleep Apnea. Noninferiority, Randomized Controlled Trial. American journal of respiratory and critical care medicine. 2017;196(9):1181-90.515159.Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines for adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2009(2):CD007736.535460.Vallbo AB, Hagbarth KE. Impulses recorded with micro-electrodes in human muscle nerves during stimulation of mechanoreceptors and voluntary contractions. Electroencephalogr Clin Neurophysiol. 1967;23(4):392.561967;23(4):392.5756586060For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	41	41	apnea severity: relationship to overnight rostral fluid shift. Journal of clinical sleep medicine : JCSM : official
434356.Bittencourt LR, Suchecki D, Tufik S, Peres C, Togeiro SM, Bagnato MC, et al. The variability of the4444apnoea-hypopnoea index. Journal of sleep research. 2001;10(3):245-51.454557.Stradling JR, Barbour C, Pitson DJ, Davies RJ. Automatic nasal continuous positive airway pressure4646titration in the laboratory: patient outcomes. Thorax. 1997;52(1):72-5.474758.Corral J, Sanchez-Quiroga MA, Carmona-Bernal C, Sanchez-Armengol A, de la Torre AS, Duran-Cantolla4848J, et al. Conventional Polysomnography Is Not Necessary for the Management of Most Patients with Suspected4949Obstructive Sleep Apnea. Noninferiority, Randomized Controlled Trial. American journal of respiratory and critical care medicine. 2017;196(9):1181-90.515159.Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines for adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2009(2):CD007736.535460.Vallbo AB, Hagbarth KE. Impulses recorded with micro-electrodes in human muscle nerves during stimulation of mechanoreceptors and voluntary contractions. Electroencephalogr Clin Neurophysiol. 1967;23(4):392.56561967;23(4):392.5820For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	42	42	publication of the American Academy of Sleep Medicine. 2015;11(2):149-56.
4444apnoea-hypopnoea index. Journal of sleep research. 2001;10(3):245-51.454557. Stradling JR, Barbour C, Pitson DJ, Davies RJ. Automatic nasal continuous positive airway pressure4646titration in the laboratory: patient outcomes. Thorax. 1997;52(1):72-5.474758. Corral J, Sanchez-Quiroga MA, Carmona-Bernal C, Sanchez-Armengol A, de la Torre AS, Duran-Cantolla4848J, et al. Conventional Polysomnography Is Not Necessary for the Management of Most Patients with Suspected4949Obstructive Sleep Apnea. Noninferiority, Randomized Controlled Trial. American journal of respiratory and505159. Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to improve usage5252of continuous positive airway pressure machines for adults with obstructive sleep apnoea. Cochrane Database535460. Vallbo AB, Hagbarth KE. Impulses recorded with micro-electrodes in human muscle nerves during5455stimulation of mechanoreceptors and voluntary contractions. Electroencephalogr Clin Neurophysiol.55561967;23(4):392.582359For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	43	43	56. Bittencourt LR, Suchecki D, Tufik S, Peres C, Togeiro SM, Bagnato MC, et al. The variability of the
454557.Stradling JR, Barbour C, Pitson DJ, Davies RJ. Automatic nasal continuous positive airway pressure4646titration in the laboratory: patient outcomes. Thorax. 1997;52(1):72-5.474758.Corral J, Sanchez-Quiroga MA, Carmona-Bernal C, Sanchez-Armengol A, de la Torre AS, Duran-Cantolla4848J, et al. Conventional Polysomnography Is Not Necessary for the Management of Most Patients with Suspected4949Obstructive Sleep Apnea. Noninferiority, Randomized Controlled Trial. American journal of respiratory and5050critical care medicine. 2017;196(9):1181-90.515159.Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to improve usage5252of continuous positive airway pressure machines for adults with obstructive sleep apnoea. Cochrane Database535460.5455stimulation of mechanoreceptors and voluntary contractions. Electroencephalogr Clin Neurophysiol.55561967;23(4):392.582360For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	44	44	apnoea-hypopnoea index. Journal of sleep research. 2001;10(3):245-51.
4646titration in the laboratory: patient outcomes. Thorax. 1997;52(1):72-5.474758.Corral J, Sanchez-Quiroga MA, Carmona-Bernal C, Sanchez-Armengol A, de la Torre AS, Duran-Cantolla4848J, et al. Conventional Polysomnography Is Not Necessary for the Management of Most Patients with Suspected4949Obstructive Sleep Apnea. Noninferiority, Randomized Controlled Trial. American journal of respiratory and50critical care medicine. 2017;196(9):1181-90.515159.525253545460.54545556561967;23(4):392.5758582360For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	45	45	57. Stradling JR, Barbour C, Pitson DJ, Davies RJ. Automatic nasal continuous positive airway pressure
474758.Corral J, Sanchez-Quiroga MA, Carmona-Bernal C, Sanchez-Armengol A, de la Torre AS, Duran-Cantolla4848J, et al. Conventional Polysomnography Is Not Necessary for the Management of Most Patients with Suspected4949Obstructive Sleep Apnea. Noninferiority, Randomized Controlled Trial. American journal of respiratory and5050critical care medicine. 2017;196(9):1181-90.515159.Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to improve usage5253Syst Rev. 2009(2):CD007736.535460.Vallbo AB, Hagbarth KE. Impulses recorded with micro-electrodes in human muscle nerves during5455stimulation of mechanoreceptors and voluntary contractions. Electroencephalogr Clin Neurophysiol.561967;23(4):392.57582360For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	46	46	titration in the laboratory: patient outcomes. Thorax. 1997;52(1):72-5.
48J, et al. Conventional Polysomnography Is Not Necessary for the Management of Most Patients with Suspected4949Obstructive Sleep Apnea. Noninferiority, Randomized Controlled Trial. American journal of respiratory and5050critical care medicine. 2017;196(9):1181-90.515159.Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to improve usage5252of continuous positive airway pressure machines for adults with obstructive sleep apnoea. Cochrane Database535460.Vallbo AB, Hagbarth KE. Impulses recorded with micro-electrodes in human muscle nerves during5455stimulation of mechanoreceptors and voluntary contractions. Electroencephalogr Clin Neurophysiol.561967;23(4):392.582359For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	47	47	58. Corral J, Sanchez-Quiroga MA, Carmona-Bernal C, Sanchez-Armengol A, de la Torre AS, Duran-Cantolla
4949Obstructive Sleep Apnea. Noninferiority, Randomized Controlled Trial. American journal of respiratory and5050critical care medicine. 2017;196(9):1181-90.515159.Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to improve usage5252of continuous positive airway pressure machines for adults with obstructive sleep apnoea. Cochrane Database5253Syst Rev. 2009(2):CD007736.5455stimulation of mechanoreceptors and voluntary contractions. Electroencephalogr Clin Neurophysiol.55561967;23(4):392.582359For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	48	48	J, et al. Conventional Polysomnography Is Not Necessary for the Management of Most Patients with Suspected
5050critical care medicine. 2017;196(9):1181-90.515159.Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to improve usage5252of continuous positive airway pressure machines for adults with obstructive sleep apnoea. Cochrane Database5253Syst Rev. 2009(2):CD007736.535460.Vallbo AB, Hagbarth KE. Impulses recorded with micro-electrodes in human muscle nerves during5455stimulation of mechanoreceptors and voluntary contractions. Electroencephalogr Clin Neurophysiol.55561967;23(4):392.582360For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	49	49	Obstructive Sleep Apnea. Noninferiority, Randomized Controlled Trial. American journal of respiratory and
515159.Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to improve usage525253of continuous positive airway pressure machines for adults with obstructive sleep apnoea. Cochrane Database535460.Vallbo AB, Hagbarth KE. Impulses recorded with micro-electrodes in human muscle nerves during5455stimulation of mechanoreceptors and voluntary contractions. Electroencephalogr Clin Neurophysiol.561967;23(4):392.582360For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	50	50	critical care medicine. 2017;196(9):1181-90.
5252of continuous positive airway pressure machines for adults with obstructive sleep apnoea. Cochrane Database525354Syst Rev. 2009(2):CD007736.535460.Vallbo AB, Hagbarth KE. Impulses recorded with micro-electrodes in human muscle nerves during5455stimulation of mechanoreceptors and voluntary contractions. Electroencephalogr Clin Neurophysiol.55561967;23(4):392.582359For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	51	51	59. Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to improve usage
53       53       Syst Rev. 2009(2):CD007736.         53       54       60.       Vallbo AB, Hagbarth KE. Impulses recorded with micro-electrodes in human muscle nerves during         54       55       56       stimulation of mechanoreceptors and voluntary contractions. Electroencephalogr Clin Neurophysiol.         55       56       1967;23(4):392.       23         58       59       For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml       23	52	52	or continuous positive airway pressure machines for adults with obstructive sleep aphoea. Cochrane Database
54       50.       Valido AB, Hagbarth KE. Impulses recorded with micro-electrodes in numan muscle nerves during         54       55       stimulation of mechanoreceptors and voluntary contractions. Electroencephalogr Clin Neurophysiol.         55       56       1967;23(4):392.         56       57       23         58       For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	53	53	Syst Rev. 2009(2):CD007736.
55       stimulation of mechanoreceptors and voluntary contractions. Electroencephalogr Clin Neurophysiol.         55       56         56       1967;23(4):392.         57       58         58       23         59       For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	54	54 55	DU. Valido AB, Hagdarth KE. Impulses recorded with micro-electrodes in human muscle nerves during
56 57 58 59 60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	55	55 56	sumulation of mechanoreceptors and voluntary contractions. Electroencephalogr Clin Neurophysiol.
57       58       23         59       59       23         60       For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml       23	56	50	1707,23(4).372.
582359For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	57		
59       60       For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	58		าา
60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	59		23
	60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

61. Mark AL, Wallin BG. Microneurography: a technique for assessing central neural effects of adrenergic drugs on sympathetic outflow in humans. Journal of cardiovascular pharmacology. 1985;7 Suppl 8:S67-9.

62. Kimmerly DS, O'Leary DD, Shoemaker JK. Test-retest repeatability of muscle sympathetic nerve

activity: influence of data analysis and head-up tilt. Auton Neurosci. 2004;114(1-2):61-71.

63. Xie A, Skatrud JB, Crabtree DC, Puleo DS, Goodman BM, Morgan BJ. Neurocirculatory consequences of intermittent asphyxia in humans. Journal of applied physiology. 2000;89(4):1333-9.

tor occr terien ont

59

1		
2		
3	1	
4		
5		
6		
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
20 21		
∠ı ))		
∠∠ )?		
23		
24		
25		
20		
27		
20		
29		
20 21		
וכ כי		
2∠ 22		
27		
24 25		
33		
30 27		
ے/ مو		
20 20		
27 10		
40 11		
41 40		
42 12		
45 11		
44 45		
45		
46		
47		
48 40		
49		
50		
51		
52		
53		
54		
55		
56		
57		



Figure 1. Settings, acquisition, recording and reporting of muscle sympathetic nerve activity (MSNA). Measurement of MSNA is obtained by placement of an un-insulated tungsten register electrode in the peroneal nerve in the popliteal fossae or close to the fibula head. The objective is to reach post ganglionic efferent sympathetic neurons. Potential voltage signal is recorded between the nerve electrode and a reference electrode placed on the external side of the knee. The acquired electrical signal is then amplified, band-filtered (700 to 2000 Hz), rectified and integrated. Sympathetic burst, which correspond to nerve firing, are detected and scored using an automatic software in order to minimize subjective interpretation of the signal MSNA results may be expressed in number of bursts per min or per 100 heart beats, Burst/min and bursts/100 heart beats respectively or using the sum of areas under the curve of all burst in arbitrary integration units per minute or per 100 heart beats, AUI/min and AUI/100 heart beats respectively.

254x142mm (300 x 300 DPI)



## Supplementary file

Patient consent forms: French and English versions.

.at English v.

**BMJ** Open

Supplementary material – Consent form (original French version)

# FORMULAIRE DE CONSENTEMENT ECLAIRÉ

Diminution du tonus sympathique chez les patients avec une apnée obstructive du sommeil: La CPP fixe est-elle plus efficace que la CPP auto ajusté?

**Titre court : APAP CPAP** 

<u>Promoteur de l'étude</u> : CHU de Grenoble – DRCI (Direction de la Recherche Clinique et Innovation) : CHU de Grenoble, CS 10217, 38043 Grenoble Cedex 09 - Tel : 04 76 76 56 09 Fax : 04 76 76 52 21

Investigateur principaL : Pr. Renaud Tamisier

Investigateurs du CHU de Grenoble participant à cette étude :

Pr Jean-Louis Pépin, Pr Renaud Tamisier, Pr Patrick Levy, Dr Marie Destors, Dr Erika Treptow, Dr. Holger Whorle: Physiologie Sommeil et Exercice - Pôle Locomotion Rééducation et Physiologie; Dr Cecile Bosc : Centre Santé et Sommeil.

Le Dr .....m'a proposé de participer à l'étude APAP CPAP. Il m'a expliqué en détail les objectifs et le déroulement de celle-ci, ainsi que les bénéfices, les risques et les contraintes.

Une notice d'information m'a été remise et j'ai eu suffisamment de temps pour la lire et prendre la décision d'accepter ou non de participer à l'étude. J'ai pu poser toutes les questions que je souhaitais et j'ai obtenu des réponses satisfaisantes. J'ai bien compris que ma participation à l'étude est volontaire et que je peux à tout moment retirer mon consentement, quelles que soient mes raisons, sans engager ma responsabilité et sans que cela modifie la qualité des soins qui me seront donnés, ni l'attention de mon médecin. J'ai bien pris connaissance que cette recherche sera conduite en conformité avec le Code de la Santé Publique.

J'ai eu l'assurance que les décisions qui s'imposent pour ma santé seront prises à tout moment, conformément à l'état actuel des connaissances médicales.

J'ai compris que je ne dois pas participer à une autre recherche en même temps que celle-ci.

En cours d'étude, tout élément nouveau me concernant et pouvant modifier mon consentement me sera communiqué.

J'accepte que les données de mon dossier médical qui se rapportent à l'étude soient accessibles aux responsables de l'étude et aux représentants des autorités de santé. A l'exception de ces personnes, qui traiteront les informations dans le plus strict respect du secret médical, mon anonymat sera préservé.

J'ai pris connaissance que cette recherche a reçu l'avis favorable du Comité de Protection des Personnes et l'autorisation de l'ANSM le.

Le promoteur de la recherche (CHU de Grenoble) a souscrit une assurance de responsabilité civile en cas de préjudice auprès de la société.

J'accepte que les données enregistrées à l'occasion de cette étude fassent l'objet d'un traitement informatisé par le service de Physiologie Sommeil et Exercice du CHU de Grenoble, responsable de l'analyse statistique. Je peux accéder, directement ou par

l'intermédiaire d'un médecin de mon choix, à l'ensemble de mes données médicales. Mon droit d'accès, de rectification et d'opposition prévu par la loi " informatique et libertés " s'exerce à tout moment, auprès du médecin en charge de la recherche.

Mon acceptation de participer à l'étude ne dégage pas les médecins et les organisateurs de l'étude de leur responsabilité. Je conserve tous mes droits garantis par la loi.

J'ai reçu une copie du présent document et j'ai été informé qu'une copie serait également conservée par l'investigateur et le promoteur dans des conditions garantissant la confidentialité et j'y consens.

Je certifie avoir lu ce document ainsi que la notice d'information et accepte de participer, librement, à cette recherche, dans les conditions qui m'ont été précisées.

En cas d'événements indésirables ou de problèmes, ou si j'ai d'autres questions au cours de ma participation, je pourrai contacter le médecin en charge de la recherche au numéro de téléphone suivant : .....

Nom / Prénom du patient :

.....

Nom du médecin :

.....

.....

.....

Date : ...../...../...../

Signature du patient :

Date : ...../...../.....

Signature du médecin :

**BMJ** Open

## Supplementary material - Consent form (English version)

## **Reduction of Sympathetic tone in OSA patients:**

## Is CPAP more effective than APAP? – a randomized, parallel clinical trial protocol

## Short title : APAP-CPAP

<u>Study Sponsor:</u> CHU de Grenoble – DRCI (Direction de la Recherche Clinique et Innovation) : CHU de Grenoble, CS 10217, 38043 Grenoble Cedex 09 - Tel : 04 76 76 56 09 Fax : 04 76 76 52 21

## Principal investigator: Renaud Tamisier

## Members of Grenoble Alpes University Hospital participating in this study :

Pr Jean-Louis Pépin, Pr Renaud Tamisier, Pr Patrick Levy, Dr Marie Destors, Dr Erika Treptow, Dr. Holger Whorle: Physiologie Sommeil et Exercice - Pôle Locomotion Rééducation et Physiologie (Physiology, Sleep and Exercise – Centre for locomotion, Reeducation and Physiology); Dr Cecile Bosc: Centre Santé et Sommeil (Health and SleepCenter).

Dr. .....has proposed that I participate in the study APAP-CPAP study. I have received detailed explanations about the objectives and procedures of the study, as well as its benefits, risks and constraints.

I have received an information sheet and I've had enough time to read it and to make the decision to participate, or not, in the study. I've had the opportunity to ask all my questions and I'vereceived satisfactory answers. I understood that my participation in the study is voluntary and that I can, at any time, withdraw my consent, whatever my reasons, without incurring any responsibility and without any modification in the treatment received.

I have been informed that this study will be conducted according to the French Code of Public Health, and have been assured that all study procedures will be made in

 accordance with the current medical recommendations.

I have understood that I should not participate in any other biomedical research protocolduring the period of this study.

During the study, I will be informed of any event concerning my health that could influence my consent.

I accept that the data in my medical file(s) related to the study will be accessible to the study's collaborators and to representatives of the health authorities. With the exception of these people, who will deal with my data in respect of professional secrecy, my anonymity will be preserved.

I have been informed that this research has been approved by the Regional Biomedical Ethics committee (*Comité de Protection de Personnes*) and authorized by the French National Agency for the Safety of Medicines and Health Products.

The sponsor of the study (Grenoble Alpes University Hospital) has contracted an additional insurance of civil responsibility in case of harms.

I accept that the data concerning me acquired during this study will be registered by the Department of Physiology, Sleep and Exercise of Grenoble Alpes University Hospital, which is responsible for the statistical analysis. I have the right to access, directly or through a physician of my choice, the set of information and medical data concerning me. At any time I will have the right of access and correction of computerized data according to the law on *"informatique et libertés"* through the physician responsible for the research.

My acceptance to participate in the study does not discharge the organizers and investigators of the study from their responsibilities. I retain all my rights guaranteed by law.

I have received a copy of the current consent sheet and I was informed that one copy will be retained by the investigator and another by the sponsor under conditions guaranteeing confidentiality.

I certify that I have read this document as well as the patient information sheet and I freely accept to participate in the study according to the conditions specified.

In case of any undesirable events or problems, or if I have any other questions during

1 2 3	my participation of the study, I may contact the	e physician responsible for the research
4 5 6 7 8	through the telephone number +33 (0)4 767655	516.
9 10	Surname / First Name of participant :	Surname of investigating physician
11 12	in :	
13 14		
15 16		
17 18 19	Date ://	Date ://
20 21	Participant's signature :	Physician's signature :
22 23		
24 25		
26 27		
28 29		
30 31		
32 33		
34		
36 37		
38		
40		
41 42		
43 44		
45 46		
47 48		
49 50		
51		
53		
54 55		
56 57		
58 59		
60		



Standard Protocol Items: Recommendations for Interventional Trials

# SPIRT 2013 Checklist: Recommended items to address in a dirical trial protocol and related documents\*

Secti o	n/item	ltem No	Description	Addressed on page number
Ad mini	istrativeinf	or mation		
Ti tl e		1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Tri a re	egistration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
		2b	All items from the World Health Organization Trial Registration Data Set	
Pr ot occ	d version	3	Dat e and version i dentifier	
Fund n	ıg	4	Sources and types of financial, material, and other support	13
Rol es a	Rol es and	5a	Na mes, affiliations, and roles of protocol contributors	1 and 16
respon	si biliti es	5b	Name and contact information for the trial sponsor	1 and 12
		5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	13
		5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21 a for data monitoring committee)	16
				1
			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3	l rtr oducti on						
4 5 6 7 8 9 10 11 12 13 14 15 6 7 8 9 10 11 12 13 14 15 6 7 8 9 10 11 12 13 14 15 6 7 22 23 24 25 26 7 28 9 30 31 22 23 24 25 27 8 9 30 31 32 33 4 5 6 7 8 9 0 11 12 34 45 6 7 8 9 0 11 12 34 45 6 7 8 9 0 11 12 34 45 6 7 8 9 0 11 12 34 45 6 7 8 9 0 11 12 34 45 6 7 8 9 0 11 12 22 23 24 25 26 7 8 9 30 31 32 33 4 5 6 7 8 9 0 11 12 3 34 5 6 7 8 9 0 11 12 22 23 24 25 26 7 8 9 30 31 32 33 4 5 36 7 8 9 0 11 22 23 24 25 26 7 8 9 31 32 33 4 5 36 7 8 9 0 11 22 23 24 25 26 7 8 9 31 32 33 4 5 36 37 8 9 0 11 22 23 24 25 26 27 28 9 30 31 32 33 4 5 36 37 38 9 0 14 2 3 34 35 36 37 38 9 0 14 2 3 34 35 36 37 38 9 0 12 33 4 5 36 37 38 9 0 14 2 3 34 5 36 37 38 9 0 12 33 4 5 36 37 38 9 0 12 33 4 5 36 37 38 9 0 12 33 4 5 36 37 38 9 0 12 33 4 5 5 6 7 8 9 0 1 2 3 3 4 5 5 6 7 8 9 9 0 1 2 3 3 4 5 5 6 7 7 8 9 9 0 1 2 3 3 4 5 5 6 7 7 8 9 0 1 2 3 3 4 5 5 6 7 7 8 9 0 1 2 3 3 3 3 5 3 7 8 9 0 1 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	Background and rationale	6a	Description of research question and justification for undertaking the trial, ind uding summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	5			
		6b	Explanation for choice of comparators	6			
	Obj ecti ves	7	Specific objectives or hypotheses	7			
	Tri al desi gn	8	Description of trial design induding type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and frame work (eg, superiority, equivalence, noninferiority, exploratory)	7			
	Met hods: Participants, interventions, and out comes						
	St udy setting	9	Description of study settings (eg. community diric, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	8 and Clincal Trials.gov (NCT03428516)			
	∃igibility criteria	10	Ind usion and exdusion criteria for participants. If applicable, eligibility criteria for study centres and ind viduals who will perform the interventions (eg, surgeons, psychotherapists)	Table 1 and page 8			
	l rt er venti ons	11a	Interventions for each group with sufficient detail to allow replication, inducing how and when they will be administered	8 and 11			
		11b	Oriteria.for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	NA			
		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg. drug tablet return, laboratory tests)	11			
		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	NA			
	Out comes	12	Primary, secondary, and other out comes, induding the specific measurement variable (eg. syst dic blood pressure), and ysis metric (eg. change from baseline, find value, time to event), method of aggregation (eg. median, proportion), and time point for each out come. Explanation of the dirical relevance of chosen efficacy and har mout comes is strongly recommended	8			
			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	2			
47							
BMJ Open

1

3

2						
3	Participant timeline	13	Time schedule of enrol ment, interventions (induding any run-ins and washouts), assessments, and visits for participants. A schematic diagramis highly recommended (see Figure)	11 and fi gure 2		
5 6 7	Samplesize	14	Estimated number of participants needed to achieve study objectives and how it was determined, ind uding dinical and statistical assumptions supporting any sample size calculations	11		
8 9 10	Recruit ment	15	Strategies for achieving a dequate participant enrol ment to reach target sample size	11 and 12		
11 12	Methods: Assignme	entofin	terventions (for controlled trials)			
12 13 14	Allocation					
15 16 17 18 19	Sequence generation	16a	Met hod of generating the allocation sequence (eg. computer-generated random numbers), and list of any factors for stratification. To reduce predict ability of a random sequence, details of any planned restriction (eg. blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	12		
20 21 22 23	Al ocati on conceal ment mechani s m	16b	Mechanism of implementing the allocation sequence (eg. central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	12		
24 25 26	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	12		
27 28 29	Blinding (masking)	17a	Who will be blinded after assign ment tointerventions (eg, trial participants, care providers, out come assessors, data analysts), and how	3, 4 and 12		
30 31 32 33		17b	If blinded, circumstances under which unblinding is per missible, and procedure for revealing a participant's all ocated intervention during the trial	NA		
34 35	Methods: Data collection, management, and analysis					
36 37 38 39 40 41 42 43	Dat a cdl ecti on met hods	18a	Flans for assessment and collection of out come, baseline, and other trial data, induding any related processes to promote data quality (eg. duplicate measurements, training of assessors) and a description of study instruments (eg. questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	8 and 11		
44 45 46 47			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml			

Page	39	of 41	
5			

BMJ Open

2 3 4		18b	Plans to promote participant retention and complete follow-up, ind ud nglist of any out come data to be collected for participants who discontinue or deviate from intervention protocols	12
5 6 7 8	Data management	19	Flansfor data entry, coding, security, and storage, induding any related processes to promote data quality (eg, double data entry, range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	12
9 10 11	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	12 and 13
12		20b	Met hods for any additional analyses (eg. subgroup and adjusted analyses)	NA
14 15 16 17		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to hand e missing data (eg, multipleimputation)	12
18 19	Met hods: Monit aring			
20 21 22 23 24	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whet her it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Atternatively, an explanation of why a DMC is not needed	no DMC
25 26 27		21b	Description of any interim analyses and stopping guidelines, ind uding who will have access to these interim results and make the final decision to terminate the trial	11 and 12
28 29 30	Har ms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trialinterventions or trial conduct	NA
31 32 33	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whet her the process will be independent from investigators and the sponsor	13 and 14
34 35	Et hics and dissemi	nation		
36 37 38 39 40 41	Research ethics approval	24	Plansfor seeking research ethics committee/institutional review board (REC/IRB) approval	13
42 43 44 45 46 47			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open

5

1 ว				
2 3 4 5	Protocd a mendments	25	Flans for communicating important protocol modifications (eg. changes to eligibility criteria, out comes, analyses) to relevant parties (eg. investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	NA
6 7 8	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	13 and 17
9 10 11 12		26b	Additional consent provisions for collection and use of participant data and bid ogical specimens in and llary studies, if applicable	NA
12 13 14	Confidenti dity	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	NA
16 17 18	Dedarationof interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	13 and 16
19 20 21	Access to data	29	Statement of who will have access to the final trial dataset, and disd osure of contractual agreements that limit such access for investigators	NA
22 23 24	Ancillaryandpost- trial care	30	Provisions, if any, for and llary and post-trial care, and for compensation to those who suffer har m from trial participation	NA
25 26 27 28	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg. via publication, reporting in results databases, or other data sharing arrangements), induding any publication restrictions	3 and 13
29		31b	Authorship eligibility guidelines and any intended use of professional witers	NA
31 32		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	none as yet
33 34	Appendices			
35 36 37 38 39 40 41 42	I rf or med consent mat eri al s	32	Model consent for m and other related documentation given to participants and authorised surrogates	Translations from Frenchoriginals available as supplementary documentation_
43 44 45 46			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

47

BMJ Open

2 3 4 5 6 7	Bid ogical 33 R ans for collection, laboratory evaluation, and storage of bid ogical specimens for genetic or molecular 7 and 10   specimens analysis in the current trial and for future use in ancillary studies, if applicable *It is strongly recommended that this checklist be read in conjunction with the SR R T 2013 Explanation & Elaboration for important diarification on the items.   Amendments to the protocol should be tracked and dated. The SR R T checklist is copyrighted by the SR R T Group under the Creative Commons
8 9	" <u>Attri buti on- Non Commer di al- No Deri vs 3 0 Unported</u> " li cense.
10 11 12 13	
14 15 16	
10 17 10	
18 19	
20 21	
22 23	
24 25	
26 27	
28 29	
30 31	
32 33	
34 35	
36 37	
38	
40	
41	6
43 44	
45 46	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
47	